<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">NPJ Parkinsons Dis</journal-id><journal-id journal-id-type="iso-abbrev">NPJ Parkinsons Dis</journal-id><journal-title-group><journal-title>NPJ Parkinson's Disease</journal-title></journal-title-group><issn pub-type="epub">2373-8057</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7181694</article-id><article-id pub-id-type="publisher-id">110</article-id><article-id pub-id-type="doi">10.1038/s41531-020-0110-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Genetic predispositions of Parkinson&#x02019;s disease revealed in patient-derived brain cells</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tran</surname><given-names>Jenne</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Anastacio</surname><given-names>Helena</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8321-0852</contrib-id><name><surname>Bardy</surname><given-names>Cedric</given-names></name><address><email>cedric.bardy@sahmri.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.430453.5</institution-id><institution>Laboratory for Human Neurophysiology and Genetics, </institution><institution>South Australian Health and Medical Research Institute (SAHMRI), </institution></institution-wrap>Adelaide, SA Australia </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0367 2697</institution-id><institution-id institution-id-type="GRID">grid.1014.4</institution-id><institution>College of Medicine and Public Health, </institution><institution>Flinders University, </institution></institution-wrap>Adelaide, SA Australia </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>4</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>4</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>6</volume><elocation-id>8</elocation-id><history><date date-type="received"><day>4</day><month>10</month><year>2019</year></date><date date-type="accepted"><day>20</day><month>3</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Parkinson&#x02019;s disease (PD) is the second most prevalent neurological disorder and has been the focus of intense investigations to understand its etiology and progression, but it still lacks a cure. Modeling diseases of the central nervous system in vitro with human induced pluripotent stem cells (hiPSC) is still in its infancy but has the potential to expedite the discovery and validation of new treatments. Here, we discuss the interplay between genetic predispositions and midbrain neuronal impairments in people living with PD. We first summarize the prevalence of causal Parkinson&#x02019;s genes and risk factors reported in 74 epidemiological and genomic studies. We then present a meta-analysis of 385 hiPSC-derived neuronal lines from 67 recent independent original research articles, which point towards specific impairments in neurons from Parkinson&#x02019;s patients, within the context of genetic predispositions. Despite the heterogeneous nature of the disease, current iPSC models reveal converging molecular pathways underlying neurodegeneration in a range of familial and sporadic forms of Parkinson&#x02019;s disease. Altogether, consolidating our understanding of robust cellular phenotypes across genetic cohorts of Parkinson&#x02019;s patients may guide future personalized drug screens in preclinical research.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Induced pluripotent stem cells</kwd><kwd>Cellular neuroscience</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001061</institution-id><institution>Rebecca L. Cooper Medical Research Foundation</institution></institution-wrap></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Parkinson's South Australia, Flinders Foundation</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Parkinson&#x02019;s Disease (PD) is a complex neurological disease, affecting approximately 2% of the population over 60 years of age. Since the first reports of PD correlation with the <italic>SNCA</italic> gene<sup><xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref></sup>, an increasing number of genomic predispositions has been identified as direct contributors or risk factors for the disease<sup><xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref></sup>. In the last decade, advances in cellular reprogramming and induced pluripotent stem cell (iPSC) technology have led to the development of patient-derived brain tissue engineering<sup><xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref></sup>. The culturing of live patient-derived neurons provides a unique opportunity to study the cellular mechanisms of genetically-linked diseases in vitro<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR20">20</xref></sup>. IPSC studies of brain disorders remain laborious and expensive, which limits the number of cell lines that can be studied in a single laboratory and may raise the issue of statistical power and reproducibility. The field is still in its infancy, and neuronal differentiation protocols are continuously improved upon, which makes technical harmonization between studies challenging<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. Like any model, iPSC studies have their weaknesses, and current limitations are being addressed collectively by the research community<sup><xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR23">23</xref></sup>. Nevertheless, the urgent need for better treatments for brain disorders justifies the requirement for pioneering iPSC studies modeling those diseases in vitro now. Since 2011, more than 385 neuronal lines from PD patients (and control subjects) have been generated across 67 original independent studies<sup><xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR92">92</xref></sup>. Independent phenotypic characterization of these lines revealed known and novel impairments in a range of cellular functions associated with PD. Moving forward, it is essential to integrate and compare the results obtained from these studies to identify the most reliable disease neuronal phenotypes before expanding the work to large drug screens. The identification of robust phenotypes of neurons derived from Parkinson&#x02019;s patients&#x02019; iPSCs may provide the basis for a new paradigm in preclinical drug development and accelerates the progression towards clinical trials.</p><p id="Par3">To quantify the prevalence and penetrance of genes known to be associated with PD, we analyzed 50 epidemiological<sup><xref ref-type="bibr" rid="CR93">93</xref>&#x02013;<xref ref-type="bibr" rid="CR129">129</xref></sup> and 24 genomic studies<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR130">130</xref>&#x02013;<xref ref-type="bibr" rid="CR148">148</xref></sup> and a genome-wide association studies (GWAS) database<sup><xref ref-type="bibr" rid="CR149">149</xref></sup>. Within this context, we then examined recent findings from human induced pluripotent stem cell (hiPSC) models that shed light on the interplay between genetic predispositions and brain cell phenotypes in people living with PD. We present an analysis of 385 human iPSC-derived neuronal lines from 67 studies, which point towards specific impairments of dopaminergic neurons from people living with PD. In comparison with the prevalence of causal PD genes in epidemiological studies, our analysis underlines the current bias of PD iPSC studies towards a subset of familial genetic predispositions. We also summarize the methodological overlap and differences between these studies, which use a broad range of reprogramming methods. Finally, our meta-analysis highlights the possibility of converging molecular and cellular pathways underlying neurodegeneration in familial and sporadic PD with diverse genetic predispositions. In particular, we discuss the convergence of various genetic predispositions on the impairment of cellular pathways underlying metabolic function, synaptic communication, inflammation, and the recycling of damaged protein and organelles. The collective insights from independent iPSC disease studies, which are pioneering this blooming field of preclinical research, may guide us towards translating fundamental discoveries into effective treatments for patients.</p></sec><sec id="Sec2"><title>The interplay between genomic predispositions and environmental factors leads to Parkinson&#x02019;s</title><p id="Par4">In the mid-1990s, the connection between PD and underlying genetic mutations was established<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR150">150</xref></sup>. It is now evident that varying degrees of the interplay between genomic predispositions and aging and cellular stressors impose a risk for disease<sup><xref ref-type="bibr" rid="CR151">151</xref></sup> (Fig. <xref rid="Fig1" ref-type="fig">1a</xref>). Previous studies have shown vascular insults to the brain, repeated head trauma, neuroleptic drugs, exposure to pesticides, and manganese toxicity increase the risks of developing symptoms of PD<sup><xref ref-type="bibr" rid="CR152">152</xref>&#x02013;<xref ref-type="bibr" rid="CR154">154</xref></sup>. In addition, advancing age can also cause a cascade of stressors within the substantia nigra, which weakens the neurons and their ability to respond to further insults<sup><xref ref-type="bibr" rid="CR155">155</xref>,<xref ref-type="bibr" rid="CR156">156</xref></sup>. Ultimately, the uniqueness of the interactions between genes and the environment makes the development of a single treatment for PD difficult as they give rise to a spectrum of neuronal phenotypes that can be unique to individual patients (Fig. <xref rid="Fig1" ref-type="fig">1c</xref>). The development of a model with the ability to replicate the genomic and epigenetic aspects of the disease is crucial (Fig. <xref rid="Fig1" ref-type="fig">1b</xref>). As increasing evidence suggests that genetic mutations are key modulators of disease initiation and progression, the identification and understanding of the various genomic predispositions are required for the development of better-targeted treatments to slow the disease progression.<fig id="Fig1"><label>Fig. 1</label><caption><title>A combinatorial spectrum of genetic risks, cellular stressors, and brain cell dysfunctions causes Parkinson&#x02019;s disease.</title><p><bold>a</bold> Graphical overview of PD risk associated with genomic predispositions and epigenetic factors. <bold>b</bold> Schematic overview of PD etiological trajectories in iPSC models. <bold>c</bold> Unique cellular phenotypes may cause PD symptoms in a subset of patients (individualized etiology) and the convergence of various initial causes into common cellular phenotypes may cause other symptoms (convergent etiology).</p></caption><graphic xlink:href="41531_2020_110_Fig1_HTML" id="d29e373"/></fig></p></sec><sec id="Sec3"><title>Learning from genetic analyses of PD case&#x02013;control studies</title><p id="Par5">We analyzed the reports from 12 international studies<sup><xref ref-type="bibr" rid="CR94">94</xref>,<xref ref-type="bibr" rid="CR157">157</xref>&#x02013;<xref ref-type="bibr" rid="CR167">167</xref></sup>, totaling 5650 persons living with PD in North America, Europe, and Australia. We confirmed that globally only 15% of patients report a family history of PD symptoms, while the remaining 85% of the PD population are classified as sporadic PD (Fig. <xref rid="Fig2" ref-type="fig">2a</xref>). However, the distinction between genetic predispositions in familial and sporadic PD is blurry. No single-gene mutation in PD has a 100% penetrance. Instead, most likely, multiple genetic risk factors act in synergy to increase the chances of both familial and sporadic PD. Such genetic susceptibilities interplay with aging and environmental factors in both familial and sporadic PD.<fig id="Fig2"><label>Fig. 2</label><caption><title>The genomics of Parkinson&#x02019;s disease: prevalence and penetrance.</title><p><bold>a</bold> In the world-wide population of people living with PD, ~85% of PD cases are sporadic (sPD) and the remaining are familial (fPD) (<italic>n</italic>&#x02009;=&#x02009;5650 PD cases combined, refer to &#x0201c;Methods&#x0201d;). <bold>b</bold> Genetic mutations occur at low (&#x0003c;&#x02009;1%) and varying frequencies (Freq.) in the PD world population (<italic>n</italic>=488 patients carrying mutation, 32,012 total PD cases used for analysis, refer to &#x0201c;Methods&#x0201d;). Data represented as the mean&#x000b1;SEM. <bold>c</bold> GWAS data suggests risk variants (OR&#x0003e;1.5) in fPD genes tend to be less prevalent in PD cases (<italic>n</italic>&#x02009;=&#x02009;25,243 PD cases, 41,945 healthy, refer to &#x0201c;Methods&#x0201d;). <bold>d</bold> Single nucleotide polymorphisms (SNPs) in over 44 genomic regions show significant (<italic>p</italic>&#x02009;&#x0003c;&#x02009;5&#x02009;x&#x02009;10<sup>&#x02212;8</sup>) association to PD. Each point presents an independent SNP hit associated with PD.</p></caption><graphic xlink:href="41531_2020_110_Fig2_HTML" id="d29e429"/></fig></p><p id="Par6">Mounting evidence demonstrates the role of genetic predispositions in PD pathogenesis, and the prevalence and penetrance of each variant start to emerge. Typically, it appears that the most common PD gene variants found in the global population have the lowest penetrance. On the other hand, most penetrant mutations are rare, and most often associated with familial PD. Variants on at least 16 PARK genes, referred to as &#x0201c;causal&#x0201d; because they instigate a relatively high familial inheritance of PD or early-onset PD symptoms, have been identified and are highlighted in Table <xref rid="Tab1" ref-type="table">1</xref><sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR119">119</xref>,<xref ref-type="bibr" rid="CR132">132</xref>,<xref ref-type="bibr" rid="CR135">135</xref>,<xref ref-type="bibr" rid="CR147">147</xref>,<xref ref-type="bibr" rid="CR168">168</xref>&#x02013;<xref ref-type="bibr" rid="CR178">178</xref></sup>. To estimate the frequency of these mutations in the Parkinson&#x02019;s population, we examined the published reports from 50 epidemiological studies. The high penetrance and hereditary nature of causal mutations can amplify their occurrence in specific ethnic groups (i.e., Japanese<sup><xref ref-type="bibr" rid="CR134">134</xref></sup>, Chinese<sup><xref ref-type="bibr" rid="CR133">133</xref></sup>, and Ashkenazi Jews<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>). However, globally our analysis shows that the presence of any known causal PD mutation is rare, occurring in less than 2% of the PD population (Fig. <xref rid="Fig2" ref-type="fig">2b</xref>). The two most common mutated genes associated with familial PD are <italic>LRRK2</italic> and <italic>PRKN</italic> and are reported in 0.7% and 0.3% of all the people showing PD symptoms, respectively (Fig. <xref rid="Fig2" ref-type="fig">2b</xref>). However, the frequency of at least some risk variants (OR&#x02009;&#x0003e;&#x02009;1.5), which we measured in a large genomic data set including 25,243 total PD cases (combination of NHGRI-EBI catalog and 24 independent genetic studies), appears higher than in the epidemiological studies, which would tend to focus on the variants with the highest penetrance. For example, <italic>LRRK2 G2385R</italic> is present in &#x0003e;10% of the PD patients and <italic>PRKN</italic> exon rearrangements are present in &#x0003e;3% of the patients (Fig. <xref rid="Fig2" ref-type="fig">2c</xref>). Our analysis also highlights that known mutations in familial PARK genes confer a broad range of risks to develop PD symptoms. <italic>PRKN(exon rearrangements)</italic>, <italic>LRRK2(G2019S)</italic>, <italic>GBA (L444P, N370S)</italic>, and <italic>CHCHD2(P2L)</italic> appear to be the most penetrant mutations, increasing the chances of getting PD symptoms by up to a factor 14, 10, 8 and 5, respectively (Fig. <xref rid="Fig2" ref-type="fig">2c</xref>). However, these penetrant variants are relatively rare, occurring in ~4%, 2%, 5%, and 2% of the PD population, respectively (Fig. <xref rid="Fig2" ref-type="fig">2c</xref>). Overall, the data tends to confirm that the most prevalent variants are less penetrant (See DJ-1 variants for example in Fig. <xref rid="Fig2" ref-type="fig">2c</xref>). Recent GWAS allowed for the detection of common low penetrance mutations associated with PD. To date, over 44 novel risk loci have been identified and associated with sporadic PD<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR141">141</xref>,<xref ref-type="bibr" rid="CR179">179</xref>,<xref ref-type="bibr" rid="CR180">180</xref></sup>. Mutations within these risk loci can be disease modulating (OR&#x02009;&#x0003e;&#x02009;1) or protective (OR&#x02009;&#x0003c;&#x02009;1) for PD (Fig. <xref rid="Fig2" ref-type="fig">2d</xref>). Despite GWAS and genetic studies pointing to several novel molecular targets and pathways in sporadic PD, many of them remain unconfirmed. The presence of mutations on a single risk locus often poses a low risk for disease, yet mutations in multiple risk loci can collectively be disease modulating. The lack of a preponderant single definitive causative gene for most PD patients is a challenge for both the design of experimental models and the discovery of well-targeted treatments. Novel approaches for disease modeling in vitro are required to unravel the polygenic and complex mechanisms underlying sporadic disease successfully. Brain tissue engineering from patient-derived stem cells provides a unique opportunity to fulfill such need.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Summary of Parkinson&#x02019;s genes first identified in familial and early-onset cases of PD and risk factors.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Gene (Chromosomal position)</th><th>Gene product</th><th>Function</th><th>Inheritance</th><th>Mutations studied in iPSC studies</th><th>Reference (iPSC studies)</th></tr></thead><tbody><tr><td>SNCA (4q21)</td><td>a-synuclein</td><td>Suppression of apoptosis, chaperone activity, antioxidation, neuronal differentiation, regulation of DA biosynthesis</td><td>AD</td><td>A53T; E46K; duplication; triplication</td><td><xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR33">33</xref>&#x02013;<xref ref-type="bibr" rid="CR35">35</xref>,<xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR60">60</xref>,<xref ref-type="bibr" rid="CR66">66</xref>,<xref ref-type="bibr" rid="CR73">73</xref>,<xref ref-type="bibr" rid="CR80">80</xref>,<xref ref-type="bibr" rid="CR83">83</xref>,<xref ref-type="bibr" rid="CR84">84</xref>,<xref ref-type="bibr" rid="CR89">89</xref>,<xref ref-type="bibr" rid="CR90">90</xref>,</td></tr><tr><td>PRKN(6q25.2-q27)</td><td>Parkin</td><td>Mitochondrial quality control</td><td>AR</td><td>V324A; T240R; R275W; R42P; &#x02212;1&#x02009;bp del 255A; Exon 3&#x02013;4 del; Exon 2 del; Exon 3/5 del; Exon 6/7 del; Exon 2/4 del; Exon 5/6 del; Exon5 del; Exon 3 del</td><td><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR54">54</xref>,<xref ref-type="bibr" rid="CR64">64</xref>,<xref ref-type="bibr" rid="CR68">68</xref>,<xref ref-type="bibr" rid="CR71">71</xref>,<xref ref-type="bibr" rid="CR74">74</xref>,<xref ref-type="bibr" rid="CR76">76</xref>,<xref ref-type="bibr" rid="CR77">77</xref>,<xref ref-type="bibr" rid="CR84">84</xref>,<xref ref-type="bibr" rid="CR88">88</xref>,<xref ref-type="bibr" rid="CR91">91</xref>,</td></tr><tr><td>PINK1 (1p35-p36)</td><td>PTEN-induced kinase 1</td><td>Mitochondrial quality control</td><td>AR</td><td>G309D; V170G; Q456X</td><td><xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR52">52</xref>,<xref ref-type="bibr" rid="CR62">62</xref>,<xref ref-type="bibr" rid="CR70">70</xref>,<xref ref-type="bibr" rid="CR71">71</xref>,<xref ref-type="bibr" rid="CR85">85</xref>,</td></tr><tr><td>DJ-1 (1p36)</td><td>DJ-1</td><td>Protection against oxidative stress</td><td>AR</td><td>E46D</td><td><xref ref-type="bibr" rid="CR27">27</xref></td></tr><tr><td>LRRK2 (12q12)</td><td>Leucine rich repeat kinase 2</td><td>Membrane trafficking, mitochondrial membrane maintenance</td><td>AD</td><td>G2019S; R1441C; R1441G; I2020T</td><td><xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR42">42</xref>&#x02013;<xref ref-type="bibr" rid="CR44">44</xref>,<xref ref-type="bibr" rid="CR46">46</xref>&#x02013;<xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR50">50</xref>,<xref ref-type="bibr" rid="CR51">51</xref>,<xref ref-type="bibr" rid="CR53">53</xref>,<xref ref-type="bibr" rid="CR56">56</xref>,<xref ref-type="bibr" rid="CR57">57</xref>,<xref ref-type="bibr" rid="CR61">61</xref>,<xref ref-type="bibr" rid="CR65">65</xref>,<xref ref-type="bibr" rid="CR78">78</xref>,<xref ref-type="bibr" rid="CR79">79</xref>,<xref ref-type="bibr" rid="CR82">82</xref>,<xref ref-type="bibr" rid="CR84">84</xref>,<xref ref-type="bibr" rid="CR86">86</xref>,<xref ref-type="bibr" rid="CR87">87</xref>,</td></tr><tr><td>ATP13A2 (1p36)</td><td>Cation-transporting ATPase 13A2</td><td>Cation homeostasis, lysosomal function</td><td>AR</td><td>N/A</td><td>N/A</td></tr><tr><td>VPS35 (16q11.2)</td><td>Vacuolar protein sorting 35</td><td>Recycling of membrane proteins between endosomes and the trans-Golgi network</td><td>AD</td><td>N/A</td><td>N/A</td></tr><tr><td>DNAJC6 (1p31.3)</td><td>DNAJ subfamily C member 6</td><td>Clathrin mediated endocytosis</td><td>AR</td><td>N/A</td><td>N/A</td></tr><tr><td>FBXO7 (22q12&#x02013;q13)</td><td>F-box protein 7</td><td>Phosphorylation-dependent ubiquitination</td><td>AR</td><td>N/A</td><td>N/A</td></tr><tr><td>SYNJ1 (21q22.11)</td><td>Synaptojanin-1</td><td>Regulation of synaptic vesicle endocytosis</td><td>AR</td><td>N/A</td><td>N/A</td></tr><tr><td>PLA2G6 (22q12&#x02013;q13)</td><td>Phospholipase A2, group 6</td><td>Phospholipid remodeling, mitochondrial function</td><td>AR</td><td>N/A</td><td>N/A</td></tr><tr><td>CHCHD2 (7p11.2)</td><td>Coiled-coil-helix-coiled-coil-helix domain 2</td><td>Regulation of mitochondrial metabolism under oxygen stress</td><td>AD</td><td>N/A</td><td>N/A</td></tr><tr><td>GIGYF2 (2q36&#x02013;q37)</td><td>GRB10 interacting GYF protein 2</td><td>Negative regulation of cell growth</td><td>AD</td><td>N/A</td><td>N/A</td></tr><tr><td>Omi/HTRA2 (2p13)</td><td>High-temperature requirement A2</td><td>Neuroprotection</td><td>AR</td><td>N/A</td><td>N/A</td></tr><tr><td>VPS13C (15q22.2)</td><td>Vacuolar protein sorting 13C</td><td>Maintenance of mitochondrial function</td><td>AR</td><td>N/A</td><td>N/A</td></tr><tr><td>EIF4G1 (3q27.1)</td><td>Eukaryotic translation initiation factor 4 gamma 1</td><td>Regulation of mRNAs translation</td><td>AD</td><td>N/A</td><td>N/A</td></tr><tr><td>UCHL1 (4p13)</td><td>Ubiquitin C-terminal hydrolase L1</td><td>Ubiquitin&#x02013;proteasome system and neuronal survival</td><td>AD</td><td>N/A</td><td>N/A</td></tr><tr><td>GBA (1q21)</td><td>Glucosylceramidase Beta</td><td>Lysosomal function</td><td>RF</td><td>N370S; L444P; RecNil</td><td><xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR58">58</xref>,<xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR69">69</xref>,<xref ref-type="bibr" rid="CR84">84</xref>,</td></tr><tr><td>MAPT (17q21.31)</td><td>Microtubule-associated protein Tau</td><td>Modulates the stability of axonal microtubules</td><td>RF</td><td>Haplotype H1/H2</td><td><xref ref-type="bibr" rid="CR25">25</xref></td></tr></tbody></table><table-wrap-foot><p>N/A indicates mutations not studied in iPSC-PD studies.</p><p><italic>AD</italic> autosomal dominant; <italic>AR</italic> autosomal recessive; <italic>RF</italic> risk factor; <italic>del</italic> deletion.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec4"><title>Studies of PD with patient-derived iPSCs</title><p id="Par7">The discovery of iPSC technology<sup><xref ref-type="bibr" rid="CR181">181</xref>&#x02013;<xref ref-type="bibr" rid="CR183">183</xref></sup> has offered the capacity to generate live brain tissue from healthy subjects and patients for studying neurodegenerative diseases<sup><xref ref-type="bibr" rid="CR184">184</xref></sup>. Directed reprogramming and neuronal differentiation of iPSCs allows the study of specific neuronal subtypes. Human-derived neurons offer a unique opportunity for modeling real cases of human genetic diseases in vitro. The ability to generate neurons both from PD patients and healthy control individuals allows the identification of early disease-linked phenotypes and provides a new paradigm for preclinical drug development and validation (Fig. <xref rid="Fig3" ref-type="fig">3a</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><title>Using brain cells generated from patient-derived iPSC to study PD in vitro.</title><p>Data from this figure was extracted and analyzed from 67 iPSC-PD studies, refer to &#x0201c;Methods&#x0201d;. <bold>a</bold> A schematic pipeline of in vitro disease modeling and preclinical drug screening with patient-derived brain cells. <bold>b</bold> The number of iPSC studies that used human neuronal lines with corresponding mutations on specific genes associated with PD (also refer to Table <xref rid="Tab1" ref-type="table">1</xref>). Categories in bold and darker bars represent the total number of studies examining that gene. <bold>c</bold> The types of control and PD cell lines are displayed as the percentage of total cell lines. <bold>d</bold> The number of PD and control cell lines used in iPSC-PD studies. Data presented as the mean&#x02009;&#x000b1;&#x02009;SEM. <bold>e</bold> Donor cell types and reprogramming methods used in hiPSC-PD studies. N/R indicates that details were not reported in these studies. <bold>f</bold> The diagram summarizes the different type of tissue culture trajectories used to differentiate cultures of iPSCs into midbrain neurons. Line thickness and percentages (in the &#x0201c;neurons&#x0201d; box) represent the proportion of studies in corresponding trajectories. The percentage displayed for each intermediate stage shows the proportion of studies that uses the corresponding cell type. EB embryoid bodies, NPCs neural progenitors <bold>g</bold> Neural induction duration indicates the number of days (average&#x02009;+&#x02009;range) required for the generation of terminal neural precursor cell types (last stage before neuronal maturation: NPCs, neurospheres, rosettes, or EZ spheres depending the stages that were skipped) from iPSC. <bold>h</bold> Neural maturation duration indicates the average number of weeks from terminal neural precursor cell type (NPCs or previous stage if NPC stage was skipped) to the neuronal cells used for phenotypic evaluation. <bold>i</bold> Small molecules and growth factors were used at various stages of midbrain dopaminergic neuronal differentiation. Data presented as the percentage of hiPSC-PD studies that report the corresponding factors in the tissue culture media composition. <bold>j</bold> The proportions (mean&#x02009;+&#x02009;SEM) of neurons (bIII-Tub/DAPI) and midbrain dopamine neurons (TH/DAPI) in cultures vary between differentiation protocols and trajectories. Each data point is the average percentage reported in a single study (<italic>n</italic>&#x02009;=&#x02009;33 independent studies, refer to &#x0201c;Methods&#x0201d;). The first column labeled as &#x0201c;all&#x0201d; groups all the studies regardless of their differentiation trajectories. Relevant immunohistochemistry quantification was not reported in studies using neural differentiation trajectories A and D.</p></caption><graphic xlink:href="41531_2020_110_Fig3_HTML" id="d29e1216"/></fig></p><p id="Par8">Since 2011, over 385 hiPSC lines have been generated from PD patients (<italic>n</italic>&#x02009;=&#x02009;215) and controls (<italic>n</italic>&#x02009;=&#x02009;170). Despite the large epidemiological preponderance of sporadic cases of PD (85% sporadic vs. 15% familial PD, Fig. <xref rid="Fig2" ref-type="fig">2a</xref>), only a few studies have modeled sporadic PD with iPSCs (Fig. <xref rid="Fig3" ref-type="fig">3b</xref>). Majority of iPSC-PD studies modeled LRRK2-G2019S, PRKN exon deletions, PINK1 Q456X, SNCA triplication, and GBA N370S (Fig. <xref rid="Fig3" ref-type="fig">3b</xref>). When combined all together, less than 20% of the iPSC disease lines were sporadic and 80% of the disease cell lines modeled single causal mutations occurring in familial PD (Fig. <xref rid="Fig3" ref-type="fig">3c</xref>). Extended application of iPSC technology beyond monogenic disease to multigenic sporadic disease is required to reveal cellular features relevant to the majority of people affected by PD. An increasing number of iPSC-based models of neurological and psychiatric disorders show that even complex brain disorders with limited heritability lead to neuronal phenotypes in vitro<sup><xref ref-type="bibr" rid="CR185">185</xref>&#x02013;<xref ref-type="bibr" rid="CR187">187</xref></sup>. Despite this current bias in the literature towards familial PD, these pioneer studies are extremely valuable and, in the sections below, we will compare their methods and summarize the overlap and discrepancies of the phenotypes reported in PD neuronal lines.</p></sec><sec id="Sec5"><title>How many patient neuronal lines should we use for iPSC models of PD?</title><p id="Par9">This is a crucial question for which a consensus remains difficult to reach. Due to the cumbersome and costly nature of iPSC studies, a balanced trade-off between a large number of neuronal lines and the depth of the analysis is inevitable. For comparison, other kinds of PD patient-control studies vary quite substantially from GWAS generally including thousands of case&#x02013;control subjects to postmortem brain tissue studies including cohorts of 11&#x02009;&#x000b1;&#x02009;5 patients and 8&#x02009;&#x000b1;&#x02009;6 controls, on average<sup><xref ref-type="bibr" rid="CR188">188</xref></sup>. We report here that current iPSC-PD studies, on average, use five individuals per study (two control and three patient lines) and a maximum of 12 controls and 11 PD line. Fewer than 12% (8/67) of published studies used more than ten cell lines (Fig. <xref rid="Fig3" ref-type="fig">3d</xref>)<sup><xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR56">56</xref>,<xref ref-type="bibr" rid="CR70">70</xref>,<xref ref-type="bibr" rid="CR79">79</xref>,<xref ref-type="bibr" rid="CR84">84</xref>,<xref ref-type="bibr" rid="CR92">92</xref></sup>. Interestingly, it has been estimated that sample sizes of 10&#x02013;30 individuals per hiPSC study may be required to achieve a statistical power of 80%, assuming that the cellular readouts variance is high and the disease effect is small (&#x0003e;0.7 relative heterogeneity, which is the ratio between within-group standard deviation and mean group difference)<sup><xref ref-type="bibr" rid="CR189">189</xref></sup>. In this situation, most iPSC studies of PD may fall below the suggested sample size requirements. However, it is important to note that due to the novelty of iPSC models, predicting the statistical power of a study remains approximative, and the number of lines required highly depends on the variance of the cellular phenotypes obtained with a specific analytical readout. It may be possible to reduce the variance without increasing the number of cell lines. For example, the patients from which the biopsies are taken may be selected based on gender, age, ethnicity, social context (i.e., farmers exposed to pesticides or professional athletes exposed to repetitive trauma), genotypes, and clinical severity of the symptoms. Ultimately, the clinical and genotypical homogeneity of the subjects may reduce the variance of the cellular phenotypes and may justify using a smaller number of cell lines. This may explain the current bias in the literature towards iPSC models of familial cases of PD (Fig. <xref rid="Fig3" ref-type="fig">3b, c</xref>). Contrastingly, there is an assumption that high genetic heterogeneity in sporadic disease contributes to a range of cellular phenotypes and therefore requires a higher number of cell lines to obtain statistical power<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR190">190</xref></sup>. However, this assumption might be wrong if multigenic sporadic PD predispositions converge to similar clinical symptoms caused by common brain cell phenotypes. Despite the current limitation of a relatively low number of cell lines used in each study, and regardless whether familial or sporadic patients were included, significant PD phenotypes have been reported, thus demonstrating the value of this research model. However, to translate these results into clinical trials and maximize their chance of success, validation in a larger number of cell lines is desired. Studies including a high number of cell lines will benefit from recent advances in high-content technologies. However, unfortunately, performing in-depth analysis of 10&#x02013;30 cell lines requires substantial resources that most laboratories do not have access to. The strategy taken in this review to combine the results from several independent studies may be a necessary compromise between in-depth analysis and a high number of cell lines. The optimization and harmonization of tissue culture methods may also be key to facilitate the identification of robust phenotypes across studies and will be discussed below. In addition, new methods decreasing the variance of neuronal phenotypes in iPSC models and decreasing the cost of the analyses are necessary and will also be discussed in the next sections.</p></sec><sec id="Sec6"><title>Choosing the right control: healthy matched subjects or genetically edited isogenic lines?</title><p id="Par10">Disease-linked cellular phenotypes are identified by comparing neuronal lines from patients and controls. To date, healthy subjects are the most commonly used control cell lines (Fig. <xref rid="Fig3" ref-type="fig">3c</xref>). However, differences in genetic background may give rise to variance in neuronal phenotypes that are unrelated to the disease. Some studies try to address this by using asymptomatic carriers, which are typically siblings or first-degree relatives of the patient<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR35">35</xref>,<xref ref-type="bibr" rid="CR57">57</xref>,<xref ref-type="bibr" rid="CR62">62</xref>,<xref ref-type="bibr" rid="CR69">69</xref>,<xref ref-type="bibr" rid="CR70">70</xref></sup>. Despite reducing genetic variability by around 50%, the limited availability of these controls hampers their use. In addition, asymptomatic carriers may express mild disease phenotypes<sup><xref ref-type="bibr" rid="CR57">57</xref>,<xref ref-type="bibr" rid="CR69">69</xref>,<xref ref-type="bibr" rid="CR70">70</xref></sup>, which can increase the threshold for detecting the early disease phenotypes of progressive neurodegenerative disorders in symptomatic carriers. In order to reduce further genetic heterogeneity between control and disease lines, the development of genetic editing techniques such as TALEN, ZFN, and CRISPR/Cas9 has enabled the generation of isogenic lines<sup><xref ref-type="bibr" rid="CR191">191</xref>&#x02013;<xref ref-type="bibr" rid="CR194">194</xref></sup>. Differing in only one single known mutant gene, the comparison of isogenic neurons allows the precise analysis of the role played by a specific mutation in disease modulation. Gene editing techniques have been particularly useful for studying monogenic forms of PD. Specifically, restorative isogenic lines of common genetic variants including <italic>LRRK2</italic>, <italic>SNCA</italic>, and <italic>GBA</italic> have highlighted complex roles of these mutations in protein aggregation, autophagy, and lysosomal dysfunction observed in PD<sup><xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR58">58</xref></sup>. In addition, PD mutations have been introduced into healthy subject or embryonic stem cell lines<sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR51">51</xref>,<xref ref-type="bibr" rid="CR53">53</xref>,<xref ref-type="bibr" rid="CR66">66</xref></sup>. Having access to isogenic lines minimizes genetic background variability between patient and control lines, thereby reducing the threshold of detection for disease-related cellular phenotypes. However, considering the low penetrance of most familial PD genes, it may also be argued that the &#x0201c;genetic background&#x0201d; of a patient contributes to the cellular phenotype in a multigenic synergic way.</p></sec><sec id="Sec7"><title>Generating relevant neuronal cell types for PD</title><p id="Par11">The cellular reprogramming toolbox for researchers is rapidly expanding and includes a panoply of neuronal differentiation protocols to generate cells representing various brain regions<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. PD is a debilitating motor system disorder resulting from the selective degeneration of midbrain dopamine (mDA) neurons located in the substantia nigra pars compacta. Protocols have been established to specifically generate dopaminergic neurons and brain cells with a midbrain molecular profile<sup><xref ref-type="bibr" rid="CR195">195</xref>,<xref ref-type="bibr" rid="CR196">196</xref></sup>.</p><p id="Par12">More than 86% of published hiPSC-PD studies started with donor skin cells (fibroblasts and keratinocytes) and only 5% used blood cells (peripheral blood mononuclear cells, CD34+ cord blood cells or lymphoblastoid cells) (Fig. <xref rid="Fig3" ref-type="fig">3e</xref>). More than 70% of iPSCs were generated using integrating viral vectors (retroviral and lentiviral), 17% used non-integrating viral vectors (Sendai virus) and only 2% used viral-free approaches (episomal) (Fig. <xref rid="Fig3" ref-type="fig">3e</xref>). Several neuronal differentiation methods used across the 67 iPSC-PD studies were also analyzed in this review<sup><xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR44">44</xref>,<xref ref-type="bibr" rid="CR86">86</xref>,<xref ref-type="bibr" rid="CR197">197</xref>&#x02013;<xref ref-type="bibr" rid="CR204">204</xref></sup>. Different methods followed distinct neuronal differentiation trajectories (from iPSC to neurons), involving the generation of various intermediate cell types (Fig. <xref rid="Fig3" ref-type="fig">3f</xref>). The intermediate stages may include embryoid bodies (EB, stem cells in suspension), EZ sphere (aggregates of early neural stem cells in suspension), neural rosettes (early neural stem cells with radial arrangements), neurosphere (neural progenitors in suspension), and neural progenitor cells (NPC, neural precursors with bipolar morphology). The generation of cell types such as EBs, neural rosettes, and NPCs mimics various stages of in utero neurogenesis<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. Few protocols also generated unconventional cell types such as EZ spheres<sup><xref ref-type="bibr" rid="CR202">202</xref></sup> or neurospheres<sup><xref ref-type="bibr" rid="CR205">205</xref></sup>. Such alternatives aim to eliminate laborious differentiation steps involving EB formation and manual picking of rosettes. On average, the generation of precursor cell types such as EZ spheres, neurospheres, or NPCs can range from 11 to 45 days (Fig. <xref rid="Fig3" ref-type="fig">3g</xref>) and neural maturation can range between 2 and 28 weeks (Fig. <xref rid="Fig3" ref-type="fig">3h</xref>). Temporal manipulation of small molecules and growth factors is used to induce neural induction, selective brain region patterning, differentiation, and maturation (Fig. <xref rid="Fig3" ref-type="fig">3i</xref>). Diverse combinations of molecules and choice of neural reprogramming trajectory can increase the efficiency and specificity of mDA neuronal differentiation. Midbrain DA neurons can also be generated using only small molecules or with the aid of lentiviral vectors<sup><xref ref-type="bibr" rid="CR70">70</xref>,<xref ref-type="bibr" rid="CR86">86</xref>,<xref ref-type="bibr" rid="CR200">200</xref></sup>. Varying differentiation protocols may influence the quality of cells. For example, neurons generated from floor-plate intermediates exhibited PD phenotypes, while cells generated on a stromal feeder layer from neural rosette intermediate did not<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>. Therefore, in some cases, phenotypic variability in iPSC-PD studies can be a consequence of varying neural differentiation protocols.</p></sec><sec id="Sec8"><title>Harmonizing rigorous protocols across studies</title><p id="Par13">Regardless of the differentiation method, cell cultures can be widely heterogeneous. On average, iPSC-PD studies, which use midbrain patterning protocols, yield 64% neurons and 27% dopaminergic neurons of the total cells (Fig. <xref rid="Fig3" ref-type="fig">3j</xref>). Proportions of neurons (bIII-Tub+) and dopaminergic neurons (TH+) vary vastly between studies even when using identical differentiation techniques (Fig. <xref rid="Fig3" ref-type="fig">3j</xref>). Quantitative analyses conducted at discordant timepoints along the maturation process may further contribute to differences in reported proportions of cell type between studies. In addition, arbitrary thresholds of immunocytochemical staining may alter the quantification of cell type numbers reported. Some studies exclusively focus on the analysis of dopaminergic neurons, but many others consistently report the presence of astrocytes, neural stem cells and multiple midbrain neuronal subtypes (i.e., glutaminergic and GABAergic) in their cultures<sup><xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR74">74</xref></sup>. Mixed cultures of human neurons and glia are more accurate in representing the neurophysiology of the human brain in vivo but add some variance in the model, which needs to be taken into consideration during experimental planning. For disease modeling, inconsistencies in both study design and analyses between laboratories can hinder the reproducibility of the results. The artificial nature of reprogramming protocols makes it difficult to agree on the superiority of a single protocol. As the field progresses, the gap between the quality of in vitro and in vivo brain tissue will tighten. The methods generating brain tissue as close as possible to their in vivo counterpart will become gold-standard methodologies, which will help to harmonize culture models between laboratories and may help expedite the clinical translation of the most robust and reproducible results. However, in some cases, for example large-scale studies requiring fast and cheap protocols, a trade-off between brain tissue quality and ease of the methods may be necessary.</p><p id="Par14">An alternative and complementary strategy is to use a top-to-bottom approach, which consists of identifying homogenous cell types of interest in mixed cultures before comparative analysis<sup><xref ref-type="bibr" rid="CR206">206</xref></sup>. The identification of desired cell types can be achieved with molecular or functional analyses. The selection or enrichment of specific cells, for example electrophysiologically mature dopaminergic neurons, can be achieved during the cellular reprograming process or right before the final comparative analysis. Fluorescence-activated cell sorting (FACS) can facilitate the removal of non-neural cell types to focus the analysis on a pure population of mDA neurons<sup><xref ref-type="bibr" rid="CR68">68</xref>,<xref ref-type="bibr" rid="CR69">69</xref></sup>. However, homogeneity based on single markers may be insufficient. Recent large-scale single-cell transcriptomics revealed the complexity of multiple cell types in neuronal culture as well as brain in vivo<sup><xref ref-type="bibr" rid="CR207">207</xref></sup>. We and others also reported that batch or tissue culture protocol variations, such as passage number or basal media, can generate a mixture of neurons at various electrophysiological states of maturity<sup><xref ref-type="bibr" rid="CR206">206</xref>,<xref ref-type="bibr" rid="CR208">208</xref></sup>. To ensure an unbiased comparison restricted to functionally mature neurons, a thorough analysis of neuronal properties using electrophysiological techniques is necessary. The recent development of Patch-Seq technology, which combines single-cell RNA-sequencing (RNA-seq) and patch clamping, enables electrophysiological, transcriptomic, and morphological profiling of single neurons<sup><xref ref-type="bibr" rid="CR206">206</xref>,<xref ref-type="bibr" rid="CR209">209</xref>,<xref ref-type="bibr" rid="CR210">210</xref></sup>. The multimodal characterization of cellular subtypes can be used to eliminate functional immaturity bias in iPSC-based disease modeling<sup><xref ref-type="bibr" rid="CR206">206</xref>,<xref ref-type="bibr" rid="CR210">210</xref></sup>.</p></sec><sec id="Sec9"><title>How environmental factors and aging can be recapitulated in vitro</title><p id="Par15">An obvious limitation of in vitro models is the lack of environmental context. The influence of nongenetic factors is not recapitulated in the basal phenotype of patient-derived neurons. For example, the influence of head trauma of a boxer with sporadic PD will not be recapitulated by default in reprogrammed neurons. An alternative would be to transplant the patient-derived neurons in animals and simulate the trauma on the animal. Similarly, influence of decades of aging of the human brain is difficult to reproduce in vitro in a few months within the boundaries of feasible experimental design. Brains in a dish will always be an imperfect experimental model. However, many tricks can be used to recapitulate the environmental and aging stress in vitro. Table <xref rid="Tab2" ref-type="table">2</xref> summarizes a list of reagents that have already been used in iPSC neuronal culture to mimic oxidative stress, proteostatic stress, mitochondrial stress, synaptic stress, ER stress, inflammation, and cellular aging. An interesting example is progerin, a truncated form of lamin A associated with premature aging. Increasing the expression of progerin in iPSC neurons can recapitulate at least some aspect of cellular aging in vitro<sup><xref ref-type="bibr" rid="CR71">71</xref></sup>. Human iPSC-derived dopamine neurons overexpressing progerin displayed specific phenotypes such as neuromelanin accumulation. In addition, PD patient-derived neurons revealed disease-related phenotypes that required both genetic susceptibility and induced-aging in vitro<sup><xref ref-type="bibr" rid="CR71">71</xref></sup>.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Cellular stressors used in hiPSC-PD models.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Type of stressor</th><th>Reagent</th><th>What is it?</th><th>Mechanism of action</th><th>Environmental and biological relevance</th></tr></thead><tbody><tr><td rowspan="9">Proteostatic</td><td>MG132</td><td>Peptide-aldehyde (proteasome inhibitor)</td><td>Initiates apoptosis and reduces degradation of ubiquitin-conjugated proteins by inhibiting 20S proteasome activity</td><td>*</td></tr><tr><td>Cycloheximide</td><td>Naturally occurring fungicide</td><td>Inhibits global transcriptional function</td><td>*</td></tr><tr><td>Lactacystin</td><td>Proteasomal inhibitors</td><td>Inhibits ubiquitin&#x02013;proteasome proteolysis pathway</td><td>*</td></tr><tr><td>Epoxomicin</td><td>Naturally occurring proteasome inhibitor</td><td>Inhibits protein degradation by inhibiting chymotrypsin-like proteasome</td><td>Used to induce PD-like symptoms in animal models</td></tr><tr><td>Leupeptin</td><td> Naturally occurring protease inhibitor</td><td>Inhibits lysosomal proteolysis by inhibiting cysteine protease</td><td>Used to induce aging associated degeneration of neural processes in animal models</td></tr><tr><td>Ammonium Chloride</td><td> Weak Base</td><td>Inhibits lysosomal proteolysis by altering pH of lysosomes</td><td>Component of fertilizers</td></tr><tr><td>Bafilomycin</td><td> Toxic macrolide antibiotic</td><td>Inhibits autophagy by preventing maturation of autophagic vacuoles. Targets vacuolar type H+-ATPase causes lysosome neutralization and inhibition of autophagosome and lysosome fusion.</td><td> *</td></tr><tr><td>Chloroquine</td><td>Prototype anti-malarial drug</td><td>Inhibits autophagy by increasing lysosomal pH and preventing fusion of autophagosomes and lysosomes.</td><td> *</td></tr><tr><td>Rapamycin</td><td>Macrolide compound</td><td>Increases autophagy by inducing autophagosome formation via inhibition of mTOR</td><td> *</td></tr><tr><td rowspan="9">Mitochondrial</td><td>FCCP/CCCP</td><td>Protonophore (respiratory chain uncoupler)</td><td>Reduce cell respiratory capacity by inhibiting mitochondrial cell volume and membrane potential</td><td> *</td></tr><tr><td>Rotenone</td><td>Insecticide</td><td>Inhibits mitochondria respiration and ATP generation via inhibition of mitochondrial complex I</td><td>Insecticide associated with PD epidemiology</td></tr><tr><td>Valinomycin</td><td> Antibiotic/Ionophore</td><td>Induced loss of mitochondrial membrane potential and mitochondrial translocation via facilitating potassium transfer across lipid layers</td><td> *</td></tr><tr><td>Oligomycin</td><td> Antibiotic</td><td>Blocks ATP synthesis via inhibition of ATP synthase preventing oxidative phosphorylation of ADP</td><td> *</td></tr><tr><td>Antimycin A</td><td>Antibiotic</td><td>Inhibits mitochondrial electron transport by inhibition of complex III</td><td> *</td></tr><tr><td>Paraquat</td><td> Herbicide</td><td>Increases ROS</td><td>Herbicide associated with PD epidemiology</td></tr><tr><td>MPTP</td><td>Impure by-product of recreational drug design</td><td>Induces cell death due to ATP depletion via inhibition of mitochondrial complex I</td><td>Causes Parkinsonism in users</td></tr><tr><td>Maneb</td><td> Fungicide</td><td>Alters cellular redox reactions by catalysing DA oxidation and chelation of metals</td><td>Fungicide used to generate PD in animal models</td></tr><tr><td>Concanamycin A</td><td> Antibiotic</td><td>Inhibits mitophagy by preventing acidification of organelles via inhibition of H+-ATPase</td><td>*</td></tr><tr><td rowspan="4">Synaptic</td><td>KCl</td><td> Metal halide salt</td><td>Induces dopamine release by increasing calcium response</td><td>KCl found in some foods and used as a salt substitute</td></tr><tr><td>Glutamate</td><td> Neurotransmitter</td><td>Activates extra-synaptic and synaptic excitatory glutamatergic receptors via AMPA, NMDA Kainite receptors, and alterations in intracellular calcium</td><td>Main component of food flavourer monosodium glutamate (MSG)</td></tr><tr><td>Caffeine</td><td>CNS stimulant</td><td>RyR agonist that increases the calcium release from the calcium-sensitive internal stores</td><td>Widely consumed psychoactive drug present in many foods</td></tr><tr><td>Colchicine</td><td>Microtubule depolarizing agent</td><td>Inhibits microtubule polymerization by binding to tubulin</td><td>Promote neurite retraction in vitro</td></tr><tr><td rowspan="6">Oxidative</td><td>Hydrogen Peroxide</td><td>Strong oxidizer</td><td>Directly increase oxidation and ROS</td><td>Induce oxidative stress linked to aging</td></tr><tr><td>No antioxidants</td><td>Removing antioxidants from neuronal culture media</td><td>Reduce the prevention of the oxidation of molecules</td><td> Antioxidants in food</td></tr><tr><td>6-OHDA</td><td>Synthetic compound (enters neurons via neurotransmitter uptake transporters)</td><td>Produce ROS specifically in dopaminergic and noradrenergic neurons; inhibition of mitochondrial complexes I and IV</td><td>Selective destruction of DAn used to generate PD in animal models</td></tr><tr><td>Dopamine</td><td>Neurotransmitter</td><td>Induced dopamine toxicity by increased dopamine oxidation by monoamine oxidases (MAO) in cytoplasm</td><td>Mimic chronic use of Levodopa</td></tr><tr><td>Cadmium</td><td> Transition metals</td><td> Induce oxidative stress by depleting cells&#x02019; antioxidants</td><td>Heavy metals present in contaminated air, water. soil and food</td></tr><tr><td>Exogenous a-synuclein</td><td>Major component of Lewy bodies</td><td>Increase basal ROS levels</td><td>Mimic effect of a-synuclein accumulation in vitro</td></tr><tr><td rowspan="3">ER</td><td>A23187</td><td> Calcium ionophore</td><td>Induced ER stress by increasing cytosolic calcium concentrations</td><td>*</td></tr><tr><td>Brefeldin A</td><td> Fungal metabolite</td><td>Inhibits intracellular protein transport by preventing association of COP-I coat to the Golgi membrane</td><td>*</td></tr><tr><td>DTT</td><td> Reducing agent</td><td>Induces ER stress by preventing inhibition of disulfide bonds</td><td>*</td></tr><tr><td>Age-inducing</td><td>Progerin</td><td>Truncated version of the lamin A protein</td><td>Increases the frequency of unrepaired double-strand breaks in DNA</td><td>Mimics aging processes</td></tr><tr><td>Inflammation</td><td>IL-17</td><td>Hematopoietic growth factor (cytokine)</td><td>Induces inflammation through IL-17&#x02013;IL-17R signaling and activation of NFkB</td><td>Naturally occurring inflammatory cytokine</td></tr></tbody></table><table-wrap-foot><p>These compounds were used to stress cells to explore mechanisms of PD not to cause PD in models.</p><p>An asterisk indicates a synthetic compound not naturally occurring or that does not have environmental or biological relevance.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec10"><title>Human iPSC studies of PD highlight converging molecular and cellular pathways across genetic subgroups</title><p id="Par16">Our analysis of 385 iPSC-derived cell lines from 67 published studies reveals that many PD neuronal phenotypes are shared between genetically heterogeneous familial and sporadic patients (Fig. <xref rid="Fig4" ref-type="fig">4a</xref>). Notably, impairments in mechanisms involved in cellular waste recycling, mitochondrial function, neuronal morphology and physiology, and sensitivity to reactive oxygen species (ROS) are most common across patient lines with varying genetic predispositions (Fig. <xref rid="Fig4" ref-type="fig">4b</xref>). The studies measured cellular phenotypes that occurred either spontaneously or in response to chemicals mimicking cellular aging and stress (Table <xref rid="Tab2" ref-type="table">2</xref> and Fig. <xref rid="Fig4" ref-type="fig">4a, c</xref>). It is important to note that the frequency of reported phenotypes in our meta-analysis may be biased because only few studies (~19%, 13/67) reported negative results (absence of phenotypes)<sup><xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR52">52</xref>,<xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR64">64</xref>,<xref ref-type="bibr" rid="CR74">74</xref>,<xref ref-type="bibr" rid="CR76">76</xref>,<xref ref-type="bibr" rid="CR86">86</xref></sup>. In addition, most cell lines were not systematically phenotyped without prior hypothesis and thus, there is likely to be an ascertain bias in these phenotypes. Less hypothesis-driven multimodal or omics analysis will help to address such bias<sup><xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR72">72</xref>,<xref ref-type="bibr" rid="CR76">76</xref>&#x02013;<xref ref-type="bibr" rid="CR80">80</xref>,<xref ref-type="bibr" rid="CR87">87</xref>,<xref ref-type="bibr" rid="CR90">90</xref></sup>. Phenotypes caused by genomic predispositions allude to crosstalk and impairments in multiple pathways that act collectively to mediate selective degeneration of dopaminergic neurons in the substantia nigra (Fig. <xref rid="Fig4" ref-type="fig">4d</xref>) and will be discussed in detail below.<fig id="Fig4"><label>Fig. 4</label><caption><title>Phenotypic insights from iPSC studies of Parkinson&#x02019;s disease.</title><p><bold>a</bold> A heatmap representation of neuronal phenotypes reported in genetically heterogeneous PD lines examined in 67 hiPSC studies. Categories in bold represent a sum of all sub-phenotypes. Reported absences of phenotypes are not represented in the figure. <bold>b</bold> Summary of the impairments in cellular mechanisms which were reported in iPSC-PD studies. Data represented as total number of studies reporting impairment with or without induced stress (&#x0201c;after stress&#x0201d; or &#x0201c;basal&#x0201d;, respectively). <bold>c</bold> Types of artificial cellular stressors used across hiPSC-PD studies (refer to Table <xref rid="Tab2" ref-type="table">2</xref>). Data presented as the number of studies that used stressor to induce or investigate PD. <bold>d</bold> Schematic representation of crosstalk between cellular mechanisms involved in PD pathogenesis.</p></caption><graphic xlink:href="41531_2020_110_Fig4_HTML" id="d29e2142"/></fig></p><sec id="Sec11"><title>Genetic predispositions reduce mitochondrial respiration in patient-derived neurons</title><p id="Par17">Epidemiological studies outlined in Fig. <xref rid="Fig2" ref-type="fig">2</xref> have pointed to several genes involved in mitochondrial function and recycling (e.g., <italic>CHCHD2, PRKN, PLA2G6, VSP13C, PINK1, LRRK2</italic>; see also Table <xref rid="Tab1" ref-type="table">1</xref>). An increase in dysfunctional mitochondria was identified in 26 independent hiPSC-PD studies using <italic>LRRK2</italic>, <italic>PRKN</italic>, <italic>PINK1</italic>, <italic>GBA</italic>, and <italic>SNCA</italic> patient-derived neuronal lines<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR37">37</xref>&#x02013;<xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR52">52</xref>,<xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR57">57</xref>,<xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR61">61</xref>,<xref ref-type="bibr" rid="CR62">62</xref>,<xref ref-type="bibr" rid="CR64">64</xref>,<xref ref-type="bibr" rid="CR67">67</xref>,<xref ref-type="bibr" rid="CR68">68</xref>,<xref ref-type="bibr" rid="CR70">70</xref>,<xref ref-type="bibr" rid="CR71">71</xref>,<xref ref-type="bibr" rid="CR73">73</xref>,<xref ref-type="bibr" rid="CR74">74</xref>,<xref ref-type="bibr" rid="CR77">77</xref>,<xref ref-type="bibr" rid="CR85">85</xref>,<xref ref-type="bibr" rid="CR89">89</xref>,<xref ref-type="bibr" rid="CR90">90</xref></sup>. Neurons derived from PD patients displayed an increase in mitochondrial copy number<sup><xref ref-type="bibr" rid="CR62">62</xref></sup> and a greater proportion of abnormal mitochondria<sup><xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR39">39</xref></sup>. Abnormal mitochondria exhibited either signs of enlargement<sup><xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR71">71</xref></sup>, shortening<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>, thinning<sup><xref ref-type="bibr" rid="CR64">64</xref></sup>, irregular cristae structures and network<sup><xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR74">74</xref></sup>, or fragmentation<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR70">70</xref></sup>. Mitochondria in the proximal axon of neurons from individuals carrying the <italic>LRRK2 R1441C</italic> mutation were 20% shorter than individuals with <italic>LRRK2-G2019S</italic> mutations<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. An increase in bidirectional mobility of mitochondria was also reported in <italic>LRRK2</italic> lines but not in <italic>PINK1</italic><sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. Overall, cellular respiration and metabolism were altered in neuronal lines derived from <italic>LRRK2</italic>, <italic>PRKN</italic>, <italic>SNCA, PINK1</italic>, <italic>DJ-1, and GBA</italic> patients<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR58">58</xref>,<xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR61">61</xref>,<xref ref-type="bibr" rid="CR67">67</xref>,<xref ref-type="bibr" rid="CR70">70</xref>,<xref ref-type="bibr" rid="CR73">73</xref>,<xref ref-type="bibr" rid="CR83">83</xref>,<xref ref-type="bibr" rid="CR85">85</xref></sup>. Basal mitochondrial respiration is consistently compromised across PD lines, exhibited as reductions in maximal oxygen consumption rate, diminished ADP and ATP levels and NAD+/NADH redox states<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR58">58</xref>,<xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR61">61</xref>,<xref ref-type="bibr" rid="CR67">67</xref>,<xref ref-type="bibr" rid="CR73">73</xref>,<xref ref-type="bibr" rid="CR85">85</xref></sup>. Impaired mitochondrial respiration was also associated with an increase in mitochondrial ROS and lysosomal hyperactivity<sup><xref ref-type="bibr" rid="CR67">67</xref></sup>. The glycolytic rate of patient-derived neurons was higher in <italic>PINK1</italic><sup><xref ref-type="bibr" rid="CR70">70</xref></sup> and <italic>PRKN</italic> lines<sup><xref ref-type="bibr" rid="CR77">77</xref></sup>. This was not observed in the transcriptomic analysis of <italic>SNCA</italic> lines<sup><xref ref-type="bibr" rid="CR90">90</xref></sup>. An increase of passive proton leakage from the inner membrane was reported in <italic>PINK1</italic> mutant neurons but not in <italic>LRRK2</italic><sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. In addition, the degradation and translocation of mitochondrial membrane proteins such as PARKIN and MIRO1 were impaired in <italic>LRRK2</italic> and <italic>PRKN</italic> neurons<sup><xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR62">62</xref>,<xref ref-type="bibr" rid="CR73">73</xref></sup>.</p><p id="Par18">Overall neuronal metabolism may be impaired by endogenous dysfunction of mitochondria<sup><xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR37">37</xref>&#x02013;<xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR52">52</xref>,<xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR57">57</xref>,<xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR61">61</xref>,<xref ref-type="bibr" rid="CR64">64</xref>,<xref ref-type="bibr" rid="CR67">67</xref>,<xref ref-type="bibr" rid="CR68">68</xref>,<xref ref-type="bibr" rid="CR70">70</xref>,<xref ref-type="bibr" rid="CR73">73</xref>,<xref ref-type="bibr" rid="CR74">74</xref>,<xref ref-type="bibr" rid="CR77">77</xref>,<xref ref-type="bibr" rid="CR85">85</xref>,<xref ref-type="bibr" rid="CR89">89</xref>,<xref ref-type="bibr" rid="CR90">90</xref></sup>, or indirect external stressors<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR62">62</xref>,<xref ref-type="bibr" rid="CR71">71</xref>,<xref ref-type="bibr" rid="CR90">90</xref></sup>, or by abnormal recycling of damaged mitochondria<sup><xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR52">52</xref>,<xref ref-type="bibr" rid="CR68">68</xref></sup>. For example, some patient neurons displayed signs of impaired mitochondrial quality control related to aberrant mitophagy<sup><xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR52">52</xref>,<xref ref-type="bibr" rid="CR68">68</xref></sup>, mitochondrial DNA damage<sup><xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR57">57</xref></sup> and consistent decreases in mitochondrial membrane potential<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR67">67</xref>,<xref ref-type="bibr" rid="CR83">83</xref>,<xref ref-type="bibr" rid="CR85">85</xref></sup>.</p><p id="Par19">Genetic predispositions that reduce the constant supply of energy to neurons ultimately disrupt the functioning of brain circuits. Mitochondrial impairments can confer increased neuronal vulnerability to oxidative, nitro-oxidative stress, and metal ions<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR58">58</xref>,<xref ref-type="bibr" rid="CR67">67</xref>,<xref ref-type="bibr" rid="CR68">68</xref>,<xref ref-type="bibr" rid="CR74">74</xref></sup>. The high metabolic demand of substantia nigra neurons might explain their selective degeneration<sup><xref ref-type="bibr" rid="CR211">211</xref></sup>.</p></sec><sec id="Sec12"><title>Impaired oxidative stress-buffering capacity increases neuronal susceptibility to cell death in PD</title><p id="Par20">Impairments in multiple cellular mechanisms increase oxidative burden in patient-derived neurons with mutations in <italic>LRRK2</italic>, <italic>PRKN</italic>, <italic>PINK1</italic>, <italic>GBA</italic>, <italic>DJ-1</italic>, and <italic>SNCA</italic> (20 studies)<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR46">46</xref>,<xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR53">53</xref>,<xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR58">58</xref>,<xref ref-type="bibr" rid="CR68">68</xref>,<xref ref-type="bibr" rid="CR77">77</xref>,<xref ref-type="bibr" rid="CR88">88</xref>,<xref ref-type="bibr" rid="CR89">89</xref></sup>. Elevated basal ROS levels reported in patient-derived neurons increase cell susceptibility to cell death such that patient lines treated with oxidative and mitochondrial stressors (i.e., H<sub>2</sub>O<sub>2</sub>, rotenone and paraquat) exhibit significantly higher levels of the cell death marker caspase-3 compared with healthy controls<sup><xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR46">46</xref>,<xref ref-type="bibr" rid="CR68">68</xref>,<xref ref-type="bibr" rid="CR77">77</xref>,<xref ref-type="bibr" rid="CR88">88</xref></sup>. Notably, antioxidant buffering in patient lines is reduced, marked by a low level of antioxidant enzymes and the downregulation of antioxidant pathways such as NRF2 and target gene <italic>NQO1</italic><sup><xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR77">77</xref></sup>. In addition, ten studies, which did not report oxidative stress phenotypes in basal conditions, reported and increase vulnerability when oxidative stress was induced with chemicals<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR53">53</xref>,<xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR58">58</xref>,<xref ref-type="bibr" rid="CR89">89</xref></sup>. This suggests that PD genetic predispositions could be compensated by upregulating endogenous antioxidant pathways or providing antioxidant supplements. Several clinical trials testing antioxidants treatments are ongoing. However, unfortunately, so far, clinical trials failed to show that antioxidants such as MitoQ significantly slow down the progression of symptoms<sup><xref ref-type="bibr" rid="CR212">212</xref></sup>. Antioxidants may need to be combined with other treatments for more positive outcomes.</p></sec><sec id="Sec13"><title>Genetic predispositions increase the probability of protein aggregation in PD neurons</title><p id="Par21">Alpha-synuclein and Tau protein accumulation constitute the most common phenotype reported in 28 studies investigating <italic>LRRK2</italic>, <italic>PRKN</italic>, <italic>PINK1</italic>, <italic>GBA</italic>, <italic>SNCA</italic>, and <italic>MAPT</italic> lines<sup><xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR34">34</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR46">46</xref>,<xref ref-type="bibr" rid="CR48">48</xref>&#x02013;<xref ref-type="bibr" rid="CR51">51</xref>,<xref ref-type="bibr" rid="CR53">53</xref>,<xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR56">56</xref>,<xref ref-type="bibr" rid="CR58">58</xref>,<xref ref-type="bibr" rid="CR60">60</xref>,<xref ref-type="bibr" rid="CR65">65</xref>,<xref ref-type="bibr" rid="CR67">67</xref>,<xref ref-type="bibr" rid="CR69">69</xref>,<xref ref-type="bibr" rid="CR73">73</xref>,<xref ref-type="bibr" rid="CR83">83</xref></sup>. The upregulation <italic>MAPT</italic> (microtubule-associated protein tau) transcripts were associated with protein aggregation, which impaired axonal mitochondria movement and induced neurite aberrations in patient neurons<sup><xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR53">53</xref>,<xref ref-type="bibr" rid="CR213">213</xref></sup>. The accumulation of &#x003b1;-synuclein and Tau has also been noted in the varicosities of contorted and fragmented axons of patients<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. Elevated expression of <italic>SNCA</italic> mRNA was associated with the dysregulation of oxidative stress, protein aggregation, and cell death regulatory genes, proposed to induce or increase selective sensitivity of mDA neurons to these factors<sup><xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR29">29</xref></sup>. Alpha-synuclein protein levels were also elevated in patient-derived neurons<sup><xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR34">34</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR46">46</xref>,<xref ref-type="bibr" rid="CR50">50</xref>,<xref ref-type="bibr" rid="CR51">51</xref>,<xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR56">56</xref>,<xref ref-type="bibr" rid="CR65">65</xref>,<xref ref-type="bibr" rid="CR69">69</xref>,<xref ref-type="bibr" rid="CR73">73</xref>,<xref ref-type="bibr" rid="CR83">83</xref></sup>. Notably, the level of soluble<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> and monomeric<sup><xref ref-type="bibr" rid="CR28">28</xref>,<xref ref-type="bibr" rid="CR46">46</xref></sup> conformations of &#x003b1;-synuclein were increased. Increased events of &#x003b1;-synuclein oligomerization<sup><xref ref-type="bibr" rid="CR73">73</xref></sup>, elevated levels of insoluble oligomers<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR55">55</xref></sup> and the formation of inclusion bodies<sup><xref ref-type="bibr" rid="CR65">65</xref></sup> were also reported. Neurons derived from <italic>SNCA</italic> mutant iPSCs<sup><xref ref-type="bibr" rid="CR55">55</xref></sup> displayed an increase in the phosphorylation of &#x003b1;-synuclein at residue S129; this was not detected in <italic>LRRK2</italic><sup><xref ref-type="bibr" rid="CR51">51</xref></sup> derived neurons. Alpha-synuclein oligomers mediated neurotoxicity through metal redox reactions and increased the formation of fibril aggregates, forming Lewy bodies<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. Nevertheless, neurotoxicity mediated by protein aggregation can be a consequence of impairments in various contributing cellular mechanisms including inflammation, mitochondrial function, autophagy and stress, suggesting a role in late PD pathogenesis<sup><xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR44">44</xref></sup>.</p></sec><sec id="Sec14"><title>Dysregulation of autophagy and protein ubiquitination contributes to neurodegeneration</title><p id="Par22">Across 15 hiPSC studies, evidence of impaired protein degradation in <italic>LRRK2</italic>, <italic>PRKN</italic>, <italic>GBA</italic>, <italic>DJ-1</italic>, <italic>SNCA</italic>, and sporadic PD lines has been reported<sup><xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR48">48</xref>&#x02013;<xref ref-type="bibr" rid="CR50">50</xref>,<xref ref-type="bibr" rid="CR53">53</xref>,<xref ref-type="bibr" rid="CR56">56</xref>,<xref ref-type="bibr" rid="CR58">58</xref>,<xref ref-type="bibr" rid="CR63">63</xref>,<xref ref-type="bibr" rid="CR69">69</xref>,<xref ref-type="bibr" rid="CR75">75</xref></sup>. Unbiased pathway analysis of cysteine-modified proteins revealed an enrichment of proteins involved in the ubiquitination and removal of unfolded protein<sup><xref ref-type="bibr" rid="CR76">76</xref></sup>. Accumulation of autophagosomes and increased expression of key autophagy regulators (i.e., beclin1, p62) were also consistently noted in PD neurons, suggestive of an upregulation of autophagy initiation<sup><xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR56">56</xref>,<xref ref-type="bibr" rid="CR74">74</xref></sup>. Increased protein levels of the autophagy marker LC3B-II in <italic>LRRK2 I2020T</italic> were associated with increased markers of protein oxidation<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>. However, reductions in microtubule-associated protein light chain 3 (LC3) and lysosomal marker colocalization reflective of unsuccessful autolysosome formation and maturation implied disturbances in autophagy progression<sup><xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR56">56</xref></sup>. Increasing genetic, epidemiological, and clinical studies draw biochemical and cellular links between PD and lysosomal storage disorders<sup><xref ref-type="bibr" rid="CR214">214</xref>,<xref ref-type="bibr" rid="CR215">215</xref></sup>. Mutations in lysosomal genes such as <italic>GBA, SMPD1</italic>, and <italic>ATP13A2</italic> have been shown to impact the bidirectional feedback loop for processing and clearance of &#x003b1;-synuclein in PD<sup><xref ref-type="bibr" rid="CR124">124</xref>,<xref ref-type="bibr" rid="CR146">146</xref>,<xref ref-type="bibr" rid="CR216">216</xref></sup>. Signs of enlarged lysosomal compartments paired with decreased lysosomal enzymatic activity suggested that poor autophagy completion contributed to protein aggregation in PD<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR47">47</xref>,<xref ref-type="bibr" rid="CR58">58</xref>,<xref ref-type="bibr" rid="CR69">69</xref>,<xref ref-type="bibr" rid="CR92">92</xref></sup>. Interestingly, lysosomal impairment in sporadic patient-derived neurons was observed at a later timepoint (180 days) compared with <italic>DJ-1</italic> mutant neurons (70 days)<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. Young-onset iPSC models of PD revealed cycloheximide treatment specifically slowed the degradation rate of &#x003b1;-synuclein<sup><xref ref-type="bibr" rid="CR92">92</xref></sup>. The dysregulation of ubiquitin genes also increased the susceptibility of patient neurons to proteasome stress<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. Dysregulated autophagy and ubiquitin&#x02013;proteasome mechanisms were associated with an increase in extracellular &#x003b1;-synuclein in patient&#x02019;s dopamine neurons<sup><xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR58">58</xref></sup>. In addition, patient-derived neurons exhibited poor ability to degrade mutant <italic>LRRK2</italic> protein compared with wildtype<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>. LRRK2 (G2019S) mutant protein displayed enhanced-binding to the lysosomal membrane and prevented the assembly of chaperone-mediated autophagy<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>. The inhibitory effect resulted in decreased degradation of long-lived proteins, which may result in unwanted protein&#x02013;protein interactions mediating neurodegeneration<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>. PD genetic predispositions favoring either aberrant protein degradation or accumulation in patient-derived neurons were associated with increased vulnerability to proteasomal and oxidative stresses, and contributed to accelerated neurodegeneration<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR53">53</xref>,<xref ref-type="bibr" rid="CR58">58</xref></sup>.</p></sec><sec id="Sec15"><title>Patient-derived neurons exhibit morphological signs of neurodegeneration</title><p id="Par23">Fifteen hiPSC-PD studies investigating <italic>LRRK2</italic>, <italic>PRKN, SNCA</italic>, and sporadic patient-derived lines reported alterations in neurite process morphology<sup><xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR51">51</xref>,<xref ref-type="bibr" rid="CR53">53</xref>,<xref ref-type="bibr" rid="CR54">54</xref>,<xref ref-type="bibr" rid="CR56">56</xref>,<xref ref-type="bibr" rid="CR60">60</xref>,<xref ref-type="bibr" rid="CR65">65</xref>,<xref ref-type="bibr" rid="CR67">67</xref>,<xref ref-type="bibr" rid="CR71">71</xref>,<xref ref-type="bibr" rid="CR76">76</xref>,<xref ref-type="bibr" rid="CR82">82</xref>,<xref ref-type="bibr" rid="CR88">88</xref></sup>. Consistently, studies reported reductions in neurite length, branching, and network complexity<sup><xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR51">51</xref>,<xref ref-type="bibr" rid="CR53">53</xref>,<xref ref-type="bibr" rid="CR54">54</xref>,<xref ref-type="bibr" rid="CR56">56</xref>,<xref ref-type="bibr" rid="CR60">60</xref>,<xref ref-type="bibr" rid="CR65">65</xref>,<xref ref-type="bibr" rid="CR67">67</xref>,<xref ref-type="bibr" rid="CR71">71</xref>,<xref ref-type="bibr" rid="CR76">76</xref>,<xref ref-type="bibr" rid="CR82">82</xref>,<xref ref-type="bibr" rid="CR88">88</xref></sup>. However, incidences of hyperbranching<sup><xref ref-type="bibr" rid="CR26">26</xref></sup> and lack of neurite alterations have also been reported<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>. In addition, irregular presynaptic membranous inclusions and dystrophic synaptic structures were reported in a neuronal model of synucleinopathy<sup><xref ref-type="bibr" rid="CR73">73</xref></sup>. The exact mechanism underlying neurite alterations in PD neurons remains unclear and can be attributed either to dysfunction in neurite morphogenesis or increased neurite deterioration<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. Elevation in autophagic flux, in response to &#x003b1;-synuclein and Tau accumulation, was associated with the reduction of neurite structure and outgrowth in patient lines<sup><xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR53">53</xref></sup>. Induction of the initiation of autophagy or inhibition of its completion also greatly exacerbated the neurite alterations in patient dopamine neurons<sup><xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR56">56</xref></sup>. Microtubule instability induced by the depolymerizing agent colchicine and loss of <italic>PRKN</italic> function also resulted in neural aberrations, though not specifically in TH+ cells<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>. Both autophagy and microtubule polymerization play key roles in neurite injury, growth and axonal formation, and impairments in either of these mechanisms can mediate the neurite alterations observed in PD neurons<sup><xref ref-type="bibr" rid="CR217">217</xref>,<xref ref-type="bibr" rid="CR218">218</xref></sup>.</p></sec><sec id="Sec16"><title>Synaptic dysfunction increases dopamine oxidation in PD leading to neurodegenerative processes</title><p id="Par24">Twelve human iPSC studies examining <italic>LRRK2</italic>, <italic>SNCA</italic>, <italic>GBA</italic>, and sporadic PD reported signs of impaired synaptic function<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR40">40</xref>&#x02013;<xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR47">47</xref>&#x02013;<xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR56">56</xref>,<xref ref-type="bibr" rid="CR60">60</xref>,<xref ref-type="bibr" rid="CR69">69</xref>,<xref ref-type="bibr" rid="CR71">71</xref>,<xref ref-type="bibr" rid="CR91">91</xref></sup>. Dysregulation of genes involved in synaptogenesis, synaptic vesicle mechanisms, synaptic transmission, and regulation of neurotransmitter release have been identified in <italic>SNCA</italic>, <italic>LRRK2</italic>, and <italic>PRKN</italic> patient-derived lines<sup><xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR92">92</xref></sup>. <italic>LRRK2 I2020T</italic> mutation decreased the spontaneous calcium-dependent release of dopamine<sup><xref ref-type="bibr" rid="CR48">48</xref></sup> but not <italic>PRKN</italic> mutant<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. The loss of PARKIN in patient midbrain neurons has been shown to downregulate dopamine reuptake machinery<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. Downregulation of synaptic proteins involved in synaptic vesicle endocytosis was associated with an increase of cytosolic dopamine<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>. Elevated levels of cytosolic dopamine mediate dopamine toxicity and contribute to neural damage and degeneration<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR69">69</xref>,<xref ref-type="bibr" rid="CR75">75</xref></sup>. Excessive oxidation of dopamine by variants of monoamine oxidases in the cytoplasm increases the formation of ROS and toxic quinones, contributing to neurodegeneration<sup><xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR69">69</xref></sup>. Disruption of calcium homeostasis and endoplasmic reticular (ER) stress may mediate excessive neurotransmitter release. RNA-seq analyses also revealed an enrichment of genes associated with ER stress in PD patient-derived neurons<sup><xref ref-type="bibr" rid="CR80">80</xref>,<xref ref-type="bibr" rid="CR90">90</xref></sup>. More than 50% of generated patient lines overexpressing &#x003b1;-synuclein displayed signs of impaired electrophysiological activity, most notably demonstrated by reduced action potentials upon stimulation<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>. Neurons derived from <italic>SNCA, LRRK2, GBA</italic>, and sporadic patients also exhibited delayed or the absence of firing synchronicity, a decrease in the number of active channels and firing rates, as well as reduced spontaneous activity<sup><xref ref-type="bibr" rid="CR41">41</xref>&#x02013;<xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR56">56</xref>,<xref ref-type="bibr" rid="CR69">69</xref></sup>. It has been suggested that, in vivo, neurons may go successively through hypo- and hyperactive phases, possibly as a homeostatic response to the cytotoxic effect of synaptic dysfunction<sup><xref ref-type="bibr" rid="CR219">219</xref></sup>. Such phases remain to be described with human iPSC-derived neurons in vitro, but multiple genetic predispositions appear to directly or indirectly impair synaptic function, which contributes to a vicious neurodegenerative cascade.</p></sec><sec id="Sec17"><title>Neuroinflammation exacerbates neurodegeneration in sporadic PD</title><p id="Par25">Midbrain neurons derived from sporadic patients showed increased susceptibility to the effects of adaptive immune cells<sup><xref ref-type="bibr" rid="CR72">72</xref></sup>. Sporadic patient neuronal lines co-cultured with T-lymphocytes exhibited substantial signs of cell death mediated by IL-17&#x02013;IL-17R signaling and activation of NFkB<sup><xref ref-type="bibr" rid="CR72">72</xref></sup>. Similarly, IL-17 treatment resulted in increased neuronal death<sup><xref ref-type="bibr" rid="CR72">72</xref></sup>. Inflammation in the central nervous system and periphery are key hallmarks of PD<sup><xref ref-type="bibr" rid="CR220">220</xref></sup>. Increasing evidence implicates the role of microglia in neuronal loss, though the underlying mechanisms remain to be determined<sup><xref ref-type="bibr" rid="CR221">221</xref>,<xref ref-type="bibr" rid="CR222">222</xref></sup>. RNA-seq analysis of astrocytes derived from <italic>LRRK2-G2019S</italic> iPSCs highlighted dysregulation in genes involved in the extracellular matrix, which may reduce the neuroprotective capacity of astrocytes in PD<sup><xref ref-type="bibr" rid="CR78">78</xref></sup>. Investigating the role of neuroinflammation in patient-derived microglia may also contribute to the understanding of the selective vulnerability of mDA neurons in sporadic and late-onset PD<sup><xref ref-type="bibr" rid="CR223">223</xref></sup>.</p></sec><sec id="Sec18"><title>Genetic predispositions reducing differentiation yield of mDA neurons</title><p id="Par26">In vitro neural development was impaired in neural lines derived from patients carrying <italic>LRRK2, PRKN, SNCA</italic>, and sporadic mutations<sup><xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR74">74</xref>,<xref ref-type="bibr" rid="CR93">93</xref></sup>. In four independent studies, the differentiation potential of neural progenitor cells derived from patients was significantly reduced, demonstrated by low yields of neurons in comparison with control lines<sup><xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR74">74</xref>,<xref ref-type="bibr" rid="CR81">81</xref>,<xref ref-type="bibr" rid="CR94">94</xref></sup>. A recent review presented the idea that PD is attributed to significant neurodevelopmental defects, which may increase the susceptibility for disease onset<sup><xref ref-type="bibr" rid="CR224">224</xref></sup>. If confirmed, identifying genetic predispositions that contribute to early developmental defects in iPSC-PD may assist the development of novel PD therapies. However, these phenotypes may appear in conflict with other studies<sup><xref ref-type="bibr" rid="CR53">53</xref>,<xref ref-type="bibr" rid="CR55">55</xref>,<xref ref-type="bibr" rid="CR76">76</xref></sup> capable of generating functional neurons from cell lines with similar mutations. The differences could be due to varying protocols, which may be more or less stressful for the cells.</p></sec><sec id="Sec19"><title>Epigenomic alterations linked with PD in patient-derived neurons</title><p id="Par27">The ability to capture unique epigenomic alterations associated with PD remains an important challenge. Reprogramming fibroblasts to iPSCs may erase age-associated<sup><xref ref-type="bibr" rid="CR225">225</xref></sup> and naive epigenetic signatures which could contribute to sporadic PD pathophysiology<sup><xref ref-type="bibr" rid="CR226">226</xref></sup>. However, an epigenetic phenotype was reported in iPSC-derived PD patient neurons<sup><xref ref-type="bibr" rid="CR79">79</xref>,<xref ref-type="bibr" rid="CR89">89</xref></sup>. Neuronal lines derived from LRRK2 and sporadic patients exhibited epigenomic alterations when compared with healthy controls<sup><xref ref-type="bibr" rid="CR79">79</xref></sup>. Hypermethylation was prominent in gene regulatory regions associated with the downregulation of transcription factors FOXA1, NR3C1, HNF4A, and FOSL2<sup><xref ref-type="bibr" rid="CR79">79</xref></sup>. Interestingly, <italic>LRRK2</italic> mutant and sporadic PD patient neurons shared similar methylation patterns, which were absent in the original donor fibroblasts<sup><xref ref-type="bibr" rid="CR79">79</xref></sup>. A spontaneous increase in the number of DNA strand breaks and genomic damage<sup><xref ref-type="bibr" rid="CR89">89</xref></sup> in PD patient-derived neurons could indirectly impact genomic regulation.</p></sec></sec><sec id="Sec20"><title>Do iPSC-PD models exhibit similar neural phenotypes to those observed in rodent models?</title><p id="Par28">The use of rodent models to simulate human pathologies associated with PD has been extensively reviewed<sup><xref ref-type="bibr" rid="CR227">227</xref>&#x02013;<xref ref-type="bibr" rid="CR230">230</xref></sup>. PD pathogenesis is mostly induced in animal models with 6-OHDA, rotenone, MPTP, paraquat, and amphetamine<sup><xref ref-type="bibr" rid="CR231">231</xref></sup>. These models induce substantia nigra dopaminergic neuron death through inhibition of mitochondrial function and increasing production of ROS<sup><xref ref-type="bibr" rid="CR229">229</xref></sup>. Rats and mice systemically exposed to rotenone and paraquat exhibited signs of Lewy body formation<sup><xref ref-type="bibr" rid="CR232">232</xref>,<xref ref-type="bibr" rid="CR233">233</xref></sup>. Knockout and transgenic rodent models are designed to investigate the consequential pathological impacts of known PD genetic mutations. Genetic mouse models have provided a platform for the functional studies of proteins associated with PD such as PARKIN, LRRK2, DJ-1, and &#x003b1;-synuclein<sup><xref ref-type="bibr" rid="CR234">234</xref>,<xref ref-type="bibr" rid="CR235">235</xref></sup>. However, the human genetic background of idiopathic PD cannot be fully recapitulated with animal models.</p><p id="Par29">iPSC-PD patient-derived neurons displayed a reduction in striatal dopamine release, a reduction in neurite complexity, an increased in tau phosphorylation, impairments of dopamine neurotransmission, autophagy, and mitochondrial abnormalities (Fig. <xref rid="Fig4" ref-type="fig">4a, b</xref>). These impairments were also observed in transgenic mice PD models<sup><xref ref-type="bibr" rid="CR236">236</xref>&#x02013;<xref ref-type="bibr" rid="CR238">238</xref></sup>. Such correlation between models is interesting, even though some of the hypothesis-driven studies in iPSC neurons may have been biased by previous animal studies. IPSC models can also shed light on cellular phenotypes absent in animal models. For example, dopamine oxidation was present in PD iPSC-derived neurons but was not observed in neurons derived from <italic>DJ-1 KO</italic> mice iPSC<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. Any model has its advantages and limitations and animal and patient-derived neuronal models complement each other. Animal models provide the organism context that is lacking in tissue culture models, whereas patient-derived neuronal models more accurately represent human genetics, which may in turn increase chances of translational success.</p></sec><sec id="Sec21"><title>Omics analysis of patient-derived PD neurons</title><p id="Par30">To date 10/67 iPSC-PD studies analyzed have used proteomic, transcriptomic, or epigenomic profiling to phenotype PD patient-derived neurons<sup><xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR72">72</xref>,<xref ref-type="bibr" rid="CR76">76</xref>&#x02013;<xref ref-type="bibr" rid="CR80">80</xref>,<xref ref-type="bibr" rid="CR87">87</xref>,<xref ref-type="bibr" rid="CR90">90</xref></sup>. Omics analyses may be less biased and data-driven as opposed to purely hypothesis-driven<sup><xref ref-type="bibr" rid="CR239">239</xref></sup>. Data from omics studies can also help to describe biological relationships between complex intertwined cellular pathways and identify relevant druggable molecular pathways.</p><p id="Par31">Genes associated with clinical PD phenotypes such as abnormal nervous physiology phenotypes, abnormal motor capabilities, coordination, and movement phenotypes were dysregulated in iPSC neurons derived from <italic>LRRK2-G2019S</italic> patients<sup><xref ref-type="bibr" rid="CR87">87</xref></sup>. RNA-seq and proteomics analysis also revealed a heavy dysregulation of genes and proteins associated with mitochondrial function, protein ubiquitination, unfolded protein response, ER/calcium regulation, and oxidative stress in PD patient-derived neurons in comparison with healthy controls<sup><xref ref-type="bibr" rid="CR41">41</xref>,<xref ref-type="bibr" rid="CR69">69</xref>,<xref ref-type="bibr" rid="CR72">72</xref>,<xref ref-type="bibr" rid="CR77">77</xref>,<xref ref-type="bibr" rid="CR78">78</xref>,<xref ref-type="bibr" rid="CR80">80</xref>,<xref ref-type="bibr" rid="CR84">84</xref>,<xref ref-type="bibr" rid="CR87">87</xref>,<xref ref-type="bibr" rid="CR90">90</xref></sup>. In addition, the epigenome in PD-derived lines was described as uniquely aberrant compared with healthy controls<sup><xref ref-type="bibr" rid="CR79">79</xref></sup>. Together, omics studies highlighted that the proteomic, transcriptomic, and epigenomic profiles of PD patient-derived neurons exhibited disease-specific alterations, which can also correlate with other neurological diseases<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. Identifying genes that are consistently dysregulated in the same direction in PD genetic lines across independent studies will help to confirm the key common pathways involved in PD pathogenesis. Much work remains to be done in this field. New human molecular insights into PD pathogenesis will help form a stronger foundation for therapeutic development, and may also benefit other neurological diseases.</p></sec><sec id="Sec22"><title>Will findings from PD iPSC models translate to human clinical trials?</title><p id="Par32">One of the most exciting applications of patient-derived iPSC models of PD is to validate pharmacological treatments before clinical trials. The field is still at the stage of improving human brain tissue engineering, and many different protocols are being tested and developed. However, the need for progress in clinical translation for brain disorders is extremely high, and there is no time to wait for brain tissue models to be perfect. Pioneering iPSC studies pave the road to success and identify limitations which help the community to reach a consensus on the minimal requirements to model brain disorders in vitro most accurately. It seems essential to improve the efficiency of reprogramming and differentiation protocols while trying to make those models as physiological and realistic as possible<sup><xref ref-type="bibr" rid="CR208">208</xref>,<xref ref-type="bibr" rid="CR240">240</xref></sup>. Some concerns are raised that in vitro neuronal development, maturation and function might be too artificial, suggesting that the model may overlook some of the critical processes that occur in vivo. Nevertheless, some defects observed in iPSC-derived neurons have already been confirmed in human postmortem brain tissues<sup><xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR241">241</xref>&#x02013;<xref ref-type="bibr" rid="CR243">243</xref></sup>. Although this is very encouraging, it is unclear whether significant in vitro phenotypes that cannot be confirmed in postmortem brain tissue should be disregarded. Most postmortem brains also have technical limitations and may represent later stages of the disease, whereas iPSC models may represent earlier stages, preceding neurodegeneration.</p><p id="Par33">Given the apprehensions that in vitro studies may be too artificial, human iPSC-derived neural progenitors may be transplanted into animal brains<sup><xref ref-type="bibr" rid="CR244">244</xref>&#x02013;<xref ref-type="bibr" rid="CR247">247</xref></sup>. Besides ethical barriers, xenografts also raise the possibility that the healthy host tissue compensate for the impairment of the transplanted cells. Yet, if the phenotypes observed in vitro are recapitulated in vivo, pharmacological treatments could be assessed in a systemic environment, with much more realistic dosage and administration methods.</p></sec><sec id="Sec23"><title>Concluding remarks</title><p id="Par34">PD is increasingly described as a spectrum disorder, with patients experiencing a multitude of motor and non-motor symptoms in a unique way. Similarly, PD genetic predispositions are broad. Hundreds of gene variants increase the risk of PD, but no genetic mutation causes a complete penetrance. We estimated the prevalence of each of the most penetrant mutations (increasing risks by &#x0003e;5 times) to occur in &#x0003c;5% of the global PD population. Despite the broad representation of genetic predispositions in PD patients, our review of current studies using iPSC-derived brain cells demonstrates commonality in cellular impairment susceptibilities. Independent reports highlight a recurring theme around dysfunction of mitochondria, proteasomal mechanisms, synapses, inflammation, and oxidative stress regulation. Constitutive and simultaneous dysregulation of multiple pathways can become overbearing, resulting in accelerated neurodegeneration. As a result, there may be an exaggerated emphasis on pathways which may represent later stages of pathogenesis. Future work will further establish the interdependence of these cellular functions and will help to isolate the initial cause from the downstream consequence of a cellular phenotype. It is also possible that current studies are biased towards studying already known or arbitrarily chosen phenotypes, and the integration of multi-omics analysis will help address this issue. Further optimization of the brain tissue engineering methods will also reduce the threshold for detecting disease-related phenotypes from tissue culture artefacts, facilitating the identification of early cellular phenotypes. Future studies also will have to include the analysis of larger pools of patients including sporadic PD with genetic predispositions more representative of the epidemiology.</p><p id="Par35">The rapid expansion of iPSC disease modeling studies of PD is exciting. Altogether, the current work reviewed here suggests that a neuroprotective therapy, which will stop the neurodegeneration in people living with PD, will most likely require to target multiple pathways at once. The prospect of investigating the impact of multigenic predispositions on brain cell functions will provide information on key modulators of neurodegeneration in PD, and preclinical data for more personalized medicine.</p></sec><sec id="Sec24"><title>Methods</title><sec id="Sec25"><title>Meta-analysis of epidemiological PD studies</title><p id="Par36">Data from Fig. <xref rid="Fig2" ref-type="fig">2a</xref> was obtained from epidemiological studies sourced from PubMed and Google Scholar search engines using keywords &#x0201c;Parkinson&#x02019;s disease&#x0201d;, &#x0201c;prevalence&#x0201d;, &#x0201c;incidence&#x0201d;, and &#x0201c;epidemiology&#x0201d;. Twelve international studies<sup><xref ref-type="bibr" rid="CR94">94</xref>,<xref ref-type="bibr" rid="CR157">157</xref>&#x02013;<xref ref-type="bibr" rid="CR167">167</xref></sup> including a total of 5650 persons living with PD were used for the analysis. Datasets were each obtained from single independent studies (Finnish, European, Canadian, Fareo Islands, Swedish, Australian, and Norwegian populations) or combined from two independent studies (American and Caucasian populations). We estimated the proportion of fPD patients in the world population with a formula (% fPD&#x02009;=&#x02009;fPD population/total PD population).</p><p id="Par37">Data from Fig. <xref rid="Fig2" ref-type="fig">2b</xref> was obtained from epidemiological studies were identified through Google Scholar search utilizing keywords &#x0201c;Parkinson&#x0201d;, &#x0201c;genetic&#x0201d;, &#x0201c;population&#x0201d;, &#x0201c;familial&#x0201d;, and the relevant gene names (i.e. LRRK2, PRKN/PARK2, ATP13A2, SNCA, VPS35, PINK1, DJ-1, and DNAJC6). A total of 50 epidemiological studies<sup><xref ref-type="bibr" rid="CR93">93</xref>&#x02013;<xref ref-type="bibr" rid="CR129">129</xref></sup> were used for the analysis (total <italic>n</italic>&#x02009;=&#x02009;488 patients carrying various mutations and 32,012 PD cases). The frequency of mutation (PD population with mutation/total PD population) was averaged across studies examining the same gene. Only studies containing sample sizes of &#x0003e;100 subjects were included in the analysis.</p></sec><sec id="Sec26"><title>Meta-analysis of genetic and GWAS studies</title><p id="Par38">A meta-analysis of genetic and GWAS studies is displayed in Fig. <xref rid="Fig2" ref-type="fig">2c</xref>. Raw GWAS data were extracted 24 independent genetic studies<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR130">130</xref>&#x02013;<xref ref-type="bibr" rid="CR148">148</xref></sup> (identified through Google scholar search with gene name and keywords &#x0201c;Parkinson&#x02019;s&#x0201d;, &#x0201c;variant&#x0201d;, and &#x0201c;odds ratio&#x0201d;) combined with GWAS database (NHGRI-EBI Catalog, accessed 14th Jan 2019, and filtered for &#x0201c;Parkinson&#x02019;s&#x0201d; as phenotype trait<sup><xref ref-type="bibr" rid="CR149">149</xref></sup>). The collated data set consisted of 25,243 PD cases and 41,945 healthy controls. The frequency (%) of each variant was measured in 25,243 total PD cases. The odds ratio (OR) was calculated by dividing the frequency of the variant among patients by the frequency of the variant in healthy controls. Only variants with OR greater than 1.5 were plotted against the frequency.</p></sec><sec id="Sec27"><title>Data extraction from PDgene GWAS database</title><p id="Par39">GWAS data were extracted from PDgene database<sup><xref ref-type="bibr" rid="CR141">141</xref></sup> was accessed on 18th Jan 2019 (<italic>n</italic>&#x02009;=&#x02009;19,061 PD cases and healthy controls). Datasets for the genes listed under &#x0201c;Top Results&#x0201d; were filtered for <italic>p</italic>&#x02009;&#x0003c;&#x02009;5&#x02009;&#x000d7;&#x02009;10<sup>&#x02013;8</sup> and OR values were plotted on Fig. <xref rid="Fig2" ref-type="fig">2d</xref>.</p></sec><sec id="Sec28"><title>Literature search of and meta-analysis of iPSC-PD studies</title><p id="Par40">Original research papers were identified through Google Scholar search utilizing keywords &#x0201c;Parkinson&#x0201d;, &#x0201c;iPSC&#x0201d;, &#x0201c;induced pluripotency stem cell&#x0201d;, &#x0201c;patient-derived&#x0201d;, and &#x0201c;models&#x0201d;. Papers published between 2011 and 2020 which included phenotypic and/multimodal analysis of the patient-derived PD lines were selected for analysis (<italic>n</italic>&#x02009;=&#x02009;67<sup><xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR92">92</xref></sup>). The meta-analyses of these studies were displayed in Fig. <xref rid="Fig3" ref-type="fig">3b&#x02013;j</xref>.</p><p id="Par41">In Fig. <xref rid="Fig3" ref-type="fig">3j</xref>, we meta-analyzed immunocytochemistry quantifications from 33 independent iPSC-PD studies. Studies reporting TUJ1 and TUBBIII were used for calculating the percentages of neurons, both label the bIII-Tubulin protein, and the names are used interchangeably. The percentage of neurons (bIII-Tub/DAPI) was reported by 23 studies (including two of them not reporting trajectories). Percentage of TH neurons (TH+/DAPI) is averaged for 32 studies. However, 12 of these 32 studies did not directly report the percentage of TH+/DAPI but instead reported TH+/TUJ1 and TUJ1+/DAPI. In this instance, for consistency in our analysis, we estimated the proportion of TH+/DAPI with a formula (TH/DAPI&#x02009;=&#x02009;TUJ1/DAPI&#x02009;&#x000d7;&#x02009;TH/TUJ1).</p></sec></sec><sec sec-type="supplementary-material"><title>Supplementary information</title><sec id="Sec29"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41531_2020_110_MOESM1_ESM.pdf"><caption><p>nr-reporting-summary</p></caption></media></supplementary-material>
</p></sec></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><sec><title>Supplementary information</title><p><bold>Supplementary information</bold> is available for this paper at 10.1038/s41531-020-0110-8.</p></sec><ack><title>Acknowledgements</title><p>The authors wish to thank Prof. Christopher Proud, Prof Stuart Brierley, Dr Tim Sargeant, A/Prof. Ville Petteri Makinen, Dr Mark van den Hurk, and the other members of the Bardy lab for the feedback. This work was generously supported by The Parkinson&#x02019;s South Australia Foundation, Perpetual Impact Philanthropy, the Brain Foundation, Flinders Foundation, Rebecca L. Cooper Foundation, Ian Potter Foundation, Angelique and Michael Boileau Corporate Philanthropy, MRFF Australian Government and Department of Health (CB), and The Australian Government Research Training Program Scholarship (JT).</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>J.T. performed the meta-analysis of all iPSC studies and genomics studies. H.A. performed the meta-analysis of epidemiological studies. C.B. designed the study and supervised J.T. and H.A. J.T., H.A., and C.B. prepared the figures. C.B. and J.T. wrote the paper. All authors have approved the submitted version.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par42">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venda</surname><given-names>LL</given-names></name><name><surname>Cragg</surname><given-names>SJ</given-names></name><name><surname>Buchman</surname><given-names>VL</given-names></name><name><surname>Wade-Martins</surname><given-names>R</given-names></name></person-group><article-title>&#x003b1;-Synuclein and dopamine at the crossroads of Parkinson's disease</article-title><source>Trends Neurosci.</source><year>2010</year><volume>33</volume><fpage>559</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2010.09.004</pub-id><?supplied-pmid 20961626?><pub-id pub-id-type="pmid">20961626</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nussbaum</surname><given-names>RL</given-names></name></person-group><article-title>The identification of alpha-synuclein as the first Parkinson disease</article-title><source>Gene. J. Parkinsons Dis.</source><year>2017</year><volume>7</volume><fpage>S43</fpage><lpage>S49</lpage><pub-id pub-id-type="doi">10.3233/JPD-179003</pub-id><?supplied-pmid 28282812?><pub-id pub-id-type="pmid">28282812</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Athanassiadou</surname><given-names>A</given-names></name><etal/></person-group><article-title>Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding alpha-synuclein</article-title><source>Am. J. Hum. Genet.</source><year>1999</year><volume>65</volume><fpage>555</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1086/302486</pub-id><?supplied-pmid 10417297?><pub-id pub-id-type="pmid">10417297</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munoz</surname><given-names>E</given-names></name><etal/></person-group><article-title>Identification of Spanish familial Parkinson's disease and screening for the Ala53Thr mutation of the alpha-synuclein gene in early onset patients</article-title><source>Neurosci. Lett.</source><year>1997</year><volume>235</volume><fpage>57</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/S0304-3940(97)00710-6</pub-id><?supplied-pmid 9389595?><pub-id pub-id-type="pmid">9389595</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polymeropoulos</surname><given-names>MH</given-names></name><etal/></person-group><article-title>Mutation in the alpha-synuclein gene identified in families with Parkinson&#x02019;s disease</article-title><source>Science</source><year>1997</year><volume>276</volume><fpage>2045</fpage><lpage>2047</lpage><pub-id pub-id-type="doi">10.1126/science.276.5321.2045</pub-id><?supplied-pmid 9197268?><pub-id pub-id-type="pmid">9197268</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood-Kaczmar</surname><given-names>A</given-names></name><name><surname>Gandhi</surname><given-names>S</given-names></name><name><surname>Wood</surname><given-names>NW</given-names></name></person-group><article-title>Understanding the molecular causes of Parkinson&#x02019;s disease</article-title><source>Trends Mol. Med.</source><year>2006</year><volume>12</volume><fpage>521</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2006.09.007</pub-id><?supplied-pmid 17027339?><pub-id pub-id-type="pmid">17027339</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escott-Price</surname><given-names>V</given-names></name><etal/></person-group><article-title>Polygenic risk of Parkinson disease is correlated with disease age at onset</article-title><source>Ann. Neurol.</source><year>2015</year><volume>77</volume><fpage>582</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1002/ana.24335</pub-id><?supplied-pmid 25773351?><pub-id pub-id-type="pmid">25773351</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Sim&#x000f3;n-S&#x000e1;nchez, J. et al. Genome-wide association study reveals genetic risk underlying Parkinson&#x02019;s disease. <italic>Nat. Genet.</italic><bold>41</bold>, 1308&#x02013;1312 (2009).</mixed-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>D</given-names></name><etal/></person-group><article-title>A meta-analysis of genome-wide association studies identifies 17 new Parkinson&#x02019;s disease risk loci</article-title><source>Nat. Genet.</source><year>2017</year><volume>7</volume><fpage>e1002142</fpage></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>TL</given-names></name><etal/></person-group><article-title>Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease</article-title><source>Ann. Hum. Genet.</source><year>2010</year><volume>74</volume><fpage>97</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1111/j.1469-1809.2009.00560.x</pub-id><?supplied-pmid 20070850?><pub-id pub-id-type="pmid">20070850</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Genome-wide association study identifies candidate genes for Parkinson's disease in an Ashkenazi Jewish population</article-title><source>BMC Med. Genet.</source><year>2011</year><volume>12</volume><fpage>104</fpage><pub-id pub-id-type="doi">10.1186/1471-2350-12-104</pub-id><?supplied-pmid 21812969?><pub-id pub-id-type="pmid">21812969</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pankratz</surname><given-names>N</given-names></name><etal/></person-group><article-title>Genomewide association study for susceptibility genes contributing to familial Parkinson disease</article-title><source>Hum. Genet.</source><year>2009</year><volume>124</volume><fpage>593</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1007/s00439-008-0582-9</pub-id><?supplied-pmid 18985386?><pub-id pub-id-type="pmid">18985386</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saad</surname><given-names>M</given-names></name><etal/></person-group><article-title>Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson's disease in the European population</article-title><source>Hum. Mol. Genet.</source><year>2011</year><volume>20</volume><fpage>615</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddq497</pub-id><?supplied-pmid 21084426?><pub-id pub-id-type="pmid">21084426</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satake</surname><given-names>W</given-names></name><etal/></person-group><article-title>Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease</article-title><source>Nat. Genet.</source><year>2009</year><volume>41</volume><fpage>1303</fpage><lpage>1307</lpage><pub-id pub-id-type="doi">10.1038/ng.485</pub-id><?supplied-pmid 19915576?><pub-id pub-id-type="pmid">19915576</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lesage</surname><given-names>S</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name></person-group><article-title>Parkinson's disease: from monogenic forms to genetic susceptibility factors</article-title><source>Hum. Mol. Genet.</source><year>2009</year><volume>18</volume><fpage>R48</fpage><lpage>R59</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddp012</pub-id><?supplied-pmid 19297401?><pub-id pub-id-type="pmid">19297401</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parr</surname><given-names>CJC</given-names></name><name><surname>Yamanaka</surname><given-names>S</given-names></name><name><surname>Saito</surname><given-names>H</given-names></name></person-group><article-title>An update on stem cell biology and engineering for brain development</article-title><source>Mol. Psychiatry</source><year>2017</year><volume>22</volume><fpage>808</fpage><lpage>819</lpage><pub-id pub-id-type="doi">10.1038/mp.2017.66</pub-id><?supplied-pmid 28373686?><pub-id pub-id-type="pmid">28373686</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamanaka</surname><given-names>S</given-names></name></person-group><article-title>Induced pluripotent stem cells: past, present, and future</article-title><source>Cell Stem Cell</source><year>2012</year><volume>10</volume><fpage>678</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2012.05.005</pub-id><?supplied-pmid 22704507?><pub-id pub-id-type="pmid">22704507</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolmetsch</surname><given-names>R</given-names></name><name><surname>Geschwind</surname></name><name><surname>Daniel</surname><given-names>H</given-names></name></person-group><article-title>The human brain in a dish: the promise of iPSC-derived neurons</article-title><source>Cell</source><year>2011</year><volume>145</volume><fpage>831</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.05.034</pub-id><?supplied-pmid 21663789?><pub-id pub-id-type="pmid">21663789</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soldner</surname><given-names>F</given-names></name><name><surname>Jaenisch</surname><given-names>R</given-names></name></person-group><article-title>Stem cells, genome editing, and the path to translational medicine</article-title><source>Cell</source><year>2018</year><volume>175</volume><fpage>615</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.09.010</pub-id><?supplied-pmid 30340033?><pub-id pub-id-type="pmid">30340033</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soldner</surname><given-names>F</given-names></name><name><surname>Jaenisch</surname><given-names>R</given-names></name></person-group><article-title>iPSC disease modeling</article-title><source>Science</source><year>2012</year><volume>338</volume><fpage>1155</fpage><pub-id pub-id-type="doi">10.1126/science.1227682</pub-id><?supplied-pmid 23197518?><pub-id pub-id-type="pmid">23197518</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mertens</surname><given-names>J</given-names></name><name><surname>Marchetto</surname><given-names>MC</given-names></name><name><surname>Bardy</surname><given-names>C</given-names></name><name><surname>Gage</surname><given-names>FH</given-names></name></person-group><article-title>Evaluating cell reprogramming, differentiation and conversion technologies in neuroscience</article-title><source>Nat. Rev. Neurosci.</source><year>2016</year><volume>17</volume><fpage>424</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1038/nrn.2016.46</pub-id><?supplied-pmid 27194476?><pub-id pub-id-type="pmid">27194476</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saha</surname><given-names>K</given-names></name><name><surname>Jaenisch</surname><given-names>R</given-names></name></person-group><article-title>Technical challenges in using human induced pluripotent stem cells to model disease</article-title><source>Cell Stem Cell</source><year>2009</year><volume>5</volume><fpage>584</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2009.11.009</pub-id><?supplied-pmid 19951687?><pub-id pub-id-type="pmid">19951687</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haston</surname><given-names>KM</given-names></name><name><surname>Finkbeiner</surname><given-names>S</given-names></name></person-group><article-title>Clinical trials in a dish: the potential of pluripotent stem cells to develop therapies for neurodegenerative diseases</article-title><source>Annu. Rev. Pharmacol. Toxicol.</source><year>2016</year><volume>56</volume><fpage>489</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1146/annurev-pharmtox-010715-103548</pub-id><?supplied-pmid 26514199?><pub-id pub-id-type="pmid">26514199</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aboud</surname><given-names>AA</given-names></name><etal/></person-group><article-title>PARK2 patient neuroprogenitors show increased mitochondrial sensitivity to copper</article-title><source>Neurobiol. Dis.</source><year>2015</year><volume>73</volume><fpage>204</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2014.10.002</pub-id><?supplied-pmid 25315681?><pub-id pub-id-type="pmid">25315681</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beevers</surname><given-names>JE</given-names></name><etal/></person-group><article-title>MAPT genetic variation and neuronal maturity alter isoform expression affecting axonal transport in iPSC-derived dopamine neurons</article-title><source>Stem Cell Rep.</source><year>2017</year><volume>9</volume><fpage>587</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2017.06.005</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borgs</surname><given-names>L</given-names></name><etal/></person-group><article-title>Dopaminergic neurons differentiating from LRRK2 G2019S induced pluripotent stem cells show early neuritic branching defects</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>33377</fpage><pub-id pub-id-type="doi">10.1038/srep33377</pub-id><?supplied-pmid 27640816?><pub-id pub-id-type="pmid">27640816</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burbulla</surname><given-names>LF</given-names></name><etal/></person-group><article-title>Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson&#x02019;s disease</article-title><source>Science</source><year>2017</year><volume>357</volume><fpage>1255</fpage><pub-id pub-id-type="doi">10.1126/science.aam9080</pub-id><?supplied-pmid 28882997?><pub-id pub-id-type="pmid">28882997</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byers</surname><given-names>B</given-names></name><etal/></person-group><article-title>SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate [alpha]-synuclein and are susceptible to oxidative stress</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><fpage>e26159</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0026159</pub-id><?supplied-pmid 22110584?><pub-id pub-id-type="pmid">22110584</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>K-H</given-names></name><etal/></person-group><article-title>Impairment of proteasome and anti-oxidative pathways in the induced pluripotent stem cell model for sporadic Parkinson's disease</article-title><source>Parkinsonism Relat. Disord.</source><year>2016</year><volume>24</volume><fpage>81</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2016.01.001</pub-id><?supplied-pmid 26797011?><pub-id pub-id-type="pmid">26797011</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>CY</given-names></name><etal/></person-group><article-title>Identification and rescue of &#x003b1;-synuclein toxicity in Parkinson patient-derived neurons</article-title><source>Science</source><year>2013</year><volume>342</volume><fpage>983</fpage><pub-id pub-id-type="doi">10.1126/science.1245296</pub-id><?supplied-pmid 24158904?><pub-id pub-id-type="pmid">24158904</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>SunY</given-names></name><etal/></person-group><article-title>Parkin and PINK1 patient iPSC-derived midbrain dopamine neurons exhibit mitochondrial dysfunction and &#x003b1;-synuclein accumulation</article-title><source>Stem Cell Rep.</source><year>2016</year><volume>7</volume><fpage>664</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2016.08.012</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>O</given-names></name><etal/></person-group><article-title>Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson&#x02019;s disease</article-title><source>Sci. Transl. Med.</source><year>2012</year><volume>4</volume><fpage>141ra190</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3003985</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deas</surname><given-names>E</given-names></name><etal/></person-group><article-title>Alpha-synuclein oligomers interact with metal ions to induce oxidative stress and neuronal death in Parkinson's disease</article-title><source>Antioxid. Redox Signal.</source><year>2016</year><volume>24</volume><fpage>376</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1089/ars.2015.6343</pub-id><?supplied-pmid 26564470?><pub-id pub-id-type="pmid">26564470</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dettmer</surname><given-names>U</given-names></name><etal/></person-group><article-title>Parkinson-causing &#x003b1;-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation</article-title><source>Nat. Commun.</source><year>2015</year><volume>6</volume><fpage>7314</fpage><pub-id pub-id-type="doi">10.1038/ncomms8314</pub-id><?supplied-pmid 26076669?><pub-id pub-id-type="pmid">26076669</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devine</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Parkinson's disease induced pluripotent stem cells with triplication of the &#x003b1;-synuclein locus</article-title><source>Nat. Commun.</source><year>2011</year><volume>2</volume><fpage>440</fpage><pub-id pub-id-type="doi">10.1038/ncomms1453</pub-id><?supplied-pmid 21863007?><pub-id pub-id-type="pmid">21863007</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandes</surname><given-names>HugoJR</given-names></name><etal/></person-group><article-title>ER stress and autophagic perturbations lead to elevated extracellular &#x003b1;-synuclein in GBA-N370S parkinson's iPSC-derived dopamine neurons</article-title><source>Stem Cell Rep.</source><year>2016</year><volume>6</volume><fpage>342</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2016.01.013</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howlett</surname><given-names>EH</given-names></name><etal/></person-group><article-title>LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease</article-title><source>Hum. Mol. Genet.</source><year>2017</year><volume>26</volume><fpage>4340</fpage><lpage>4351</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddx320</pub-id><?supplied-pmid 28973664?><pub-id pub-id-type="pmid">28973664</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>C-H</given-names></name><etal/></person-group><article-title>Functional impairment in miro degradation and mitophagy is a shared feature in familial and sporadic Parkinson&#x02019;s disease</article-title><source>Cell Stem Cell</source><year>2016</year><volume>19</volume><fpage>709</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2016.08.002</pub-id><?supplied-pmid 27618216?><pub-id pub-id-type="pmid">27618216</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imaizumi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Mitochondrial dysfunction associated with increased oxidative stress and &#x003b1;-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue</article-title><source>Mol. Brain</source><year>2012</year><volume>5</volume><fpage>35</fpage><pub-id pub-id-type="doi">10.1186/1756-6606-5-35</pub-id><?supplied-pmid 23039195?><pub-id pub-id-type="pmid">23039195</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells</article-title><source>Nat. Commun.</source><year>2012</year><volume>3</volume><fpage>668</fpage><pub-id pub-id-type="doi">10.1038/ncomms1669</pub-id><?supplied-pmid 22314364?><pub-id pub-id-type="pmid">22314364</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kouroupi</surname><given-names>G</given-names></name><etal/></person-group><article-title>Defective synaptic connectivity and axonal neuropathology in a human iPSC-based model of familial Parkinson&#x02019;s disease</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2017</year><volume>114</volume><fpage>E3679</fpage><lpage>E3688</lpage><pub-id pub-id-type="doi">10.1073/pnas.1617259114</pub-id><?supplied-pmid 28416701?><pub-id pub-id-type="pmid">28416701</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>L</given-names></name><etal/></person-group><article-title>Molecular features underlying neurodegeneration identified through in vitro modeling of genetically diverse Parkinson&#x02019;s disease patients</article-title><source>Cell Rep.</source><year>2016</year><volume>15</volume><fpage>2411</fpage><lpage>2426</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.05.022</pub-id><?supplied-pmid 27264186?><pub-id pub-id-type="pmid">27264186</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>G-H</given-names></name><etal/></person-group><article-title>Progressive degeneration of human neural stem cells caused by pathogenic LRRK2</article-title><source>Nature</source><year>2012</year><volume>491</volume><fpage>603</fpage><pub-id pub-id-type="doi">10.1038/nature11557</pub-id><?supplied-pmid 23075850?><pub-id pub-id-type="pmid">23075850</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f3;pez de Maturana</surname><given-names>R</given-names></name><etal/></person-group><article-title>Mutations in LRRK2 impair NF-&#x003ba;B pathway in iPSC-derived neurons</article-title><source>J. Neuroinflammation</source><year>2016</year><volume>13</volume><fpage>295</fpage><pub-id pub-id-type="doi">10.1186/s12974-016-0761-x</pub-id><?supplied-pmid 27863501?><pub-id pub-id-type="pmid">27863501</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marrone</surname><given-names>L</given-names></name><etal/></person-group><article-title>Generation of iPSCs carrying a common LRRK2 risk allele for in vitro modeling of idiopathic Parkinson's disease</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><fpage>e0192497</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0192497</pub-id><?supplied-pmid 29513666?><pub-id pub-id-type="pmid">29513666</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>HaN</given-names></name><etal/></person-group><article-title>LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress</article-title><source>Cell Stem Cell</source><year>2011</year><volume>8</volume><fpage>267</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2011.01.013</pub-id><?supplied-pmid 21362567?><pub-id pub-id-type="pmid">21362567</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>M</given-names></name><name><surname>Krainc</surname><given-names>D</given-names></name></person-group><article-title>LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson's disease</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2018</year><volume>115</volume><fpage>5576</fpage><lpage>5581</lpage><pub-id pub-id-type="doi">10.1073/pnas.1717590115</pub-id><?supplied-pmid 29735704?><pub-id pub-id-type="pmid">29735704</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohta</surname><given-names>E</given-names></name><etal/></person-group><article-title>I2020T mutant LRRK2 iPSC-derived neurons in the Sagamihara family exhibit increased Tau phosphorylation through the AKT/GSK-3&#x003b2; signaling pathway</article-title><source>Hum. Mol. Genet.</source><year>2015</year><volume>24</volume><fpage>4879</fpage><lpage>4900</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddv212</pub-id><?supplied-pmid 26056228?><pub-id pub-id-type="pmid">26056228</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oliveira</surname><given-names>LMA</given-names></name><etal/></person-group><article-title>Elevated &#x003b1;-synuclein caused by SNCA gene triplication impairs neuronal differentiation and maturation in Parkinson's patient-derived induced pluripotent stem cells</article-title><source>Cell Death Dis.</source><year>2015</year><volume>6</volume><fpage>e1994</fpage><pub-id pub-id-type="doi">10.1038/cddis.2015.318</pub-id><?supplied-pmid 26610207?><pub-id pub-id-type="pmid">26610207</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orenstein</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Interplay of LRRK2 with chaperone-mediated autophagy</article-title><source>Nat. Neurosci.</source><year>2013</year><volume>16</volume><fpage>394</fpage><pub-id pub-id-type="doi">10.1038/nn.3350</pub-id><?supplied-pmid 23455607?><pub-id pub-id-type="pmid">23455607</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qing</surname><given-names>X</given-names></name><etal/></person-group><article-title>CRISPR/Cas9 and piggyBac-mediated footprint-free LRRK2-G2019S knock-in reveals neuronal complexity phenotypes and &#x003b1;-Synuclein modulation in dopaminergic neurons</article-title><source>Stem Cell Res.</source><year>2017</year><volume>24</volume><fpage>44</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.scr.2017.08.013</pub-id><?supplied-pmid 28826027?><pub-id pub-id-type="pmid">28826027</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rakovic</surname><given-names>A</given-names></name><etal/></person-group><article-title>Phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1)-dependent ubiquitination of endogenous Parkin attenuates mitophagy: study in human primary fibroblasts and induced pluripotent stem cell-derived neurons</article-title><source>J. Biol. Chem.</source><year>2013</year><volume>288</volume><fpage>2223</fpage><lpage>2237</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.391680</pub-id><?supplied-pmid 23212910?><pub-id pub-id-type="pmid">23212910</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reinhardt</surname><given-names>P</given-names></name><etal/></person-group><article-title>Genetic correction of a LRRK2 mutation in human iPSCs links Parkinsonian neurodegeneration to ERK-dependent changes in gene expression</article-title><source>Cell Stem Cell</source><year>2013</year><volume>12</volume><fpage>354</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2013.01.008</pub-id><?supplied-pmid 23472874?><pub-id pub-id-type="pmid">23472874</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Parkin mutations reduce the complexity of neuronal processes in iPSC&#x02010;derived human neurons</article-title><source>STEM CELLS</source><year>2014</year><volume>33</volume><fpage>68</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1002/stem.1854</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>ScottD</given-names></name><etal/></person-group><article-title>Isogenic human iPSC Parkinson&#x02019;s model shows nitrosative stress-induced dysfunction in MEF2-PGC1&#x003b1; transcription</article-title><source>Cell</source><year>2013</year><volume>155</volume><fpage>1351</fpage><lpage>1364</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.11.009</pub-id><?supplied-pmid 24290359?><pub-id pub-id-type="pmid">24290359</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000e1;nchez&#x02010;Dan&#x000e9;s</surname><given-names>A</given-names></name><etal/></person-group><article-title>Disease&#x02010;specific phenotypes in dopamine neurons from human iPS&#x02010;based models of genetic and sporadic Parkinson's disease</article-title><source>EMBO Mol. Med.</source><year>2012</year><volume>4</volume><fpage>380</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1002/emmm.201200215</pub-id><?supplied-pmid 22407749?><pub-id pub-id-type="pmid">22407749</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanders</surname><given-names>LH</given-names></name><etal/></person-group><article-title>LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction</article-title><source>Neurobiol. Dis.</source><year>2014</year><volume>62</volume><fpage>381</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2013.10.013</pub-id><?supplied-pmid 24148854?><pub-id pub-id-type="pmid">24148854</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sch&#x000f6;ndorf</surname><given-names>DC</given-names></name><etal/></person-group><article-title>iPSC-derived neurons from GBA1-associated Parkinson&#x02019;s disease patients show autophagic defects and impaired calcium homeostasis</article-title><source>Nat. Commun.</source><year>2014</year><volume>5</volume><fpage>4028</fpage><pub-id pub-id-type="doi">10.1038/ncomms5028</pub-id><?supplied-pmid 24905578?><pub-id pub-id-type="pmid">24905578</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sch&#x000f6;ndorf</surname><given-names>DC</given-names></name><etal/></person-group><article-title>The NAD&#x02009;+&#x02009;precursor nicotinamide riboside rescues mitochondrial defects and neuronal loss in iPSC and fly models of Parkinson&#x02019;s disease</article-title><source>Cell Rep.</source><year>2018</year><volume>23</volume><fpage>2976</fpage><lpage>2988</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.05.009</pub-id><?supplied-pmid 29874584?><pub-id pub-id-type="pmid">29874584</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwab</surname><given-names>AndrewJ</given-names></name><name><surname>Ebert</surname></name><name><surname>Allison</surname><given-names>D</given-names></name></person-group><article-title>Neurite aggregation and calcium dysfunction in iPSC-derived sensory neurons with Parkinson&#x02019;s disease-related LRRK2 G2019S mutation</article-title><source>Stem Cell Rep.</source><year>2015</year><volume>5</volume><fpage>1039</fpage><lpage>1052</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2015.11.004</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwab</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Decreased sirtuin deacetylase activity in LRRK2 G2019S iPSC-derived dopaminergic neurons</article-title><source>Stem Cell Rep.</source><year>2017</year><volume>9</volume><fpage>1839</fpage><lpage>1852</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2017.10.010</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seibler</surname><given-names>P</given-names></name><etal/></person-group><article-title>Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells</article-title><source>J. Neurosci.</source><year>2011</year><volume>31</volume><fpage>5970</fpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4441-10.2011</pub-id><?supplied-pmid 21508222?><pub-id pub-id-type="pmid">21508222</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaltouki</surname><given-names>A</given-names></name><name><surname>Hsieh</surname><given-names>CH</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>Alpha-synuclein delays mitophagy and targeting Miro rescues neuron loss in Parkinson's models</article-title><source>Acta neuropathologica</source><year>2018</year><volume>136</volume><fpage>607</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1007/s00401-018-1873-4</pub-id><?supplied-pmid 29923074?><pub-id pub-id-type="pmid">29923074</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiba-Fukushima</surname><given-names>K</given-names></name><etal/></person-group><article-title>Evidence that phosphorylated ubiquitin signaling is involved in the etiology of Parkinson's disease</article-title><source>Hum. Mol. Genet.</source><year>2017</year><volume>26</volume><fpage>3172</fpage><lpage>3185</lpage><?supplied-pmid 28541509?><pub-id pub-id-type="pmid">28541509</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skibinski</surname><given-names>G</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Cookson</surname><given-names>MR</given-names></name><name><surname>Finkbeiner</surname><given-names>S</given-names></name></person-group><article-title>Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies</article-title><source>J. Neurosci.</source><year>2014</year><volume>34</volume><fpage>418</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2712-13.2014</pub-id><?supplied-pmid 24403142?><pub-id pub-id-type="pmid">24403142</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soldner</surname><given-names>F</given-names></name><etal/></person-group><article-title>Generation of isogenic pluripotent stem cells differing exclusively at two early onset parkinson point mutations</article-title><source>Cell</source><year>2011</year><volume>146</volume><fpage>318</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.06.019</pub-id><?supplied-pmid 21757228?><pub-id pub-id-type="pmid">21757228</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>Y-C</given-names></name><name><surname>Qi</surname><given-names>X</given-names></name></person-group><article-title>Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation</article-title><source>Hum. Mol. Genet.</source><year>2013</year><volume>22</volume><fpage>4545</fpage><lpage>4561</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddt301</pub-id><?supplied-pmid 23813973?><pub-id pub-id-type="pmid">23813973</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>S</given-names></name><etal/></person-group><article-title>Efficient induction of dopaminergic neuron differentiation from induced pluripotent stem cells reveals impaired mitophagy in PARK2 neurons</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2017</year><volume>483</volume><fpage>88</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2016.12.188</pub-id><?supplied-pmid 28057485?><pub-id pub-id-type="pmid">28057485</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woodard</surname><given-names>ChrisM</given-names></name><etal/></person-group><article-title>iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson&#x02019;s disease</article-title><source>Cell Rep.</source><year>2014</year><volume>9</volume><fpage>1173</fpage><lpage>1182</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.10.023</pub-id><?supplied-pmid 25456120?><pub-id pub-id-type="pmid">25456120</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azkona</surname><given-names>G</given-names></name><etal/></person-group><article-title>LRRK2 expression is deregulated in fibroblasts and neurons from Parkinson patients with mutations in PINK1</article-title><source>Mol. Neurobiol.</source><year>2018</year><volume>55</volume><fpage>506</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1007/s12035-016-0303-7</pub-id><?supplied-pmid 27975167?><pub-id pub-id-type="pmid">27975167</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Human iPSC-based modeling of late-onset disease via progerin-induced aging</article-title><source>Cell Stem Cell</source><year>2013</year><volume>13</volume><fpage>691</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2013.11.006</pub-id><?supplied-pmid 24315443?><pub-id pub-id-type="pmid">24315443</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sommer</surname><given-names>A</given-names></name><etal/></person-group><article-title>Th17 lymphocytes induce neuronal cell death in a human iPSC-based model of Parkinson&#x02019;s disease</article-title><source>Cell Stem Cell</source><year>2018</year><volume>23</volume><fpage>123</fpage><lpage>131.e126</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2018.06.015</pub-id><?supplied-pmid 29979986?><pub-id pub-id-type="pmid">29979986</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prots</surname><given-names>I</given-names></name><etal/></person-group><article-title>alpha-Synuclein oligomers induce early axonal dysfunction in human iPSC-based models of synucleinopathies</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2018</year><volume>115</volume><fpage>7813</fpage><lpage>7818</lpage><pub-id pub-id-type="doi">10.1073/pnas.1713129115</pub-id><?supplied-pmid 29991596?><pub-id pub-id-type="pmid">29991596</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaltouki</surname><given-names>A</given-names></name><etal/></person-group><article-title>Mitochondrial alterations by PARKIN in dopaminergic neurons using PARK2 patient-specific and PARK2 knockout isogenic iPSC lines</article-title><source>Stem Cell Rep.</source><year>2015</year><volume>4</volume><fpage>847</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2015.02.019</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aflaki</surname><given-names>E</given-names></name><etal/></person-group><article-title>A new glucocerebrosidase chaperone reduces alpha-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with Gaucher disease and Parkinsonism</article-title><source>J. Neurosci.</source><year>2016</year><volume>36</volume><fpage>7441</fpage><lpage>7452</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0636-16.2016</pub-id><?supplied-pmid 27413154?><pub-id pub-id-type="pmid">27413154</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bogetofte</surname><given-names>H</given-names></name><etal/></person-group><article-title>Perturbations in RhoA signalling cause altered migration and impaired neuritogenesis in human iPSC-derived neural cells with PARK2 mutation</article-title><source>Neurobiol. Dis.</source><year>2019</year><volume>132</volume><fpage>104581</fpage><pub-id pub-id-type="doi">10.1016/j.nbd.2019.104581</pub-id><?supplied-pmid 31445161?><pub-id pub-id-type="pmid">31445161</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bogetofte</surname><given-names>H</given-names></name><etal/></person-group><article-title>PARK2 mutation causes metabolic disturbances and impaired survival of human iPSC-derived neurons</article-title><source>Front. Cell. Neurosci.</source><year>2019</year><volume>13</volume><fpage>297</fpage><pub-id pub-id-type="doi">10.3389/fncel.2019.00297</pub-id><?supplied-pmid 31333417?><pub-id pub-id-type="pmid">31333417</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Booth</surname><given-names>HDE</given-names></name><etal/></person-group><article-title>RNA sequencing reveals MMP2 and TGFB1 downregulation in LRRK2 G2019S Parkinson's iPSC-derived astrocytes</article-title><source>Neurobiol. Dis.</source><year>2019</year><volume>129</volume><fpage>56</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2019.05.006</pub-id><?supplied-pmid 31085228?><pub-id pub-id-type="pmid">31085228</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fern&#x000e1;ndez-Santiago</surname><given-names>R</given-names></name><etal/></person-group><article-title>Aberrant epigenome in iPSC-derived dopaminergic neurons from Parkinson's disease patients</article-title><source>EMBO Mol. Med.</source><year>2015</year><volume>7</volume><fpage>1529</fpage><lpage>1546</lpage><pub-id pub-id-type="doi">10.15252/emmm.201505439</pub-id><?supplied-pmid 26516212?><pub-id pub-id-type="pmid">26516212</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heman-Ackah</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Alpha-synuclein induces the unfolded protein response in Parkinson&#x02019;s disease SNCA triplication iPSC-derived neurons</article-title><source>Hum. Mol. Genet.</source><year>2017</year><volume>26</volume><fpage>4441</fpage><lpage>4450</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddx331</pub-id><?supplied-pmid 28973645?><pub-id pub-id-type="pmid">28973645</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iannielli</surname><given-names>A</given-names></name><etal/></person-group><article-title>Pharmacological inhibition of necroptosis protects from dopaminergic neuronal cell death in Parkinson&#x02019;s disease models</article-title><source>Cell Rep.</source><year>2018</year><volume>22</volume><fpage>2066</fpage><lpage>2079</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.01.089</pub-id><?supplied-pmid 29466734?><pub-id pub-id-type="pmid">29466734</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korecka</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Neurite collapse and altered ER Ca2+ control in human Parkinson disease patient iPSC-derived neurons with LRRK2 G2019S mutation</article-title><source>Stem Cell Rep.</source><year>2019</year><volume>12</volume><fpage>29</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2018.11.021</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ludtmann</surname><given-names>MHR</given-names></name><etal/></person-group><article-title>alpha-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson's disease</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>2293</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-04422-2</pub-id><?supplied-pmid 29895861?><pub-id pub-id-type="pmid">29895861</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Momcilovic</surname><given-names>O</given-names></name><etal/></person-group><article-title>Derivation, characterization, and neural differentiation of integration-free induced pluripotent stem cell lines from Parkinson's disease patients carrying SNCA, LRRK2, PARK2, and GBA mutations</article-title><source>PloS ONE</source><year>2016</year><volume>11</volume><fpage>e0154890</fpage><lpage>e0154890</lpage><pub-id pub-id-type="doi">10.1371/journal.pone.0154890</pub-id><?supplied-pmid 27191603?><pub-id pub-id-type="pmid">27191603</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morais</surname><given-names>VA</given-names></name><etal/></person-group><article-title>PINK1 loss-of-function mutations affect mitochondrial complex I activity via NdufA10 ubiquinone uncoupling</article-title><source>Science</source><year>2014</year><volume>344</volume><fpage>203</fpage><pub-id pub-id-type="doi">10.1126/science.1249161</pub-id><?supplied-pmid 24652937?><pub-id pub-id-type="pmid">24652937</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reinhardt</surname><given-names>P</given-names></name><etal/></person-group><article-title>Derivation and expansion using only small molecules of human neural progenitors for neurodegenerative disease modeling</article-title><source>PLOS ONE</source><year>2013</year><volume>8</volume><fpage>e59252</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0059252</pub-id><?supplied-pmid 23533608?><pub-id pub-id-type="pmid">23533608</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandor</surname><given-names>C</given-names></name><etal/></person-group><article-title>Transcriptomic profiling of purified patient-derived dopamine neurons identifies convergent perturbations and therapeutics for Parkinson's disease</article-title><source>Hum. Mol. Genet.</source><year>2017</year><volume>26</volume><fpage>552</fpage><lpage>566</lpage><?supplied-pmid 5409122?><pub-id pub-id-type="pmid">28096185</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabata</surname><given-names>Y</given-names></name><etal/></person-group><article-title>T-type calcium channels determine the vulnerability of dopaminergic neurons to mitochondrial stress in familial Parkinson disease</article-title><source>Stem Cell Rep.</source><year>2018</year><volume>11</volume><fpage>1171</fpage><lpage>1184</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2018.09.006</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasquez</surname><given-names>V</given-names></name><etal/></person-group><article-title>Chromatin-bound oxidized &#x003b1;-synuclein causes strand breaks in neuronal genomes in in vitro models of Parkinson's disease</article-title><source>J. Alzheimers Dis.</source><year>2017</year><volume>60</volume><fpage>S133</fpage><lpage>S150</lpage><pub-id pub-id-type="doi">10.3233/JAD-170342</pub-id><?supplied-pmid 28731447?><pub-id pub-id-type="pmid">28731447</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zambon</surname><given-names>F</given-names></name><etal/></person-group><article-title>Cellular &#x003b1;-synuclein pathology is associated with bioenergetic dysfunction in Parkinson&#x02019;s iPSC-derived dopamine neurons</article-title><source>Hum. Mol. Genet.</source><year>2019</year><volume>28</volume><fpage>2001</fpage><lpage>2013</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddz038</pub-id><?supplied-pmid 30753527?><pub-id pub-id-type="pmid">30753527</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>P</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Yan</surname><given-names>Z</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name></person-group><article-title>Dopamine induces oscillatory activities in human midbrain neurons with Parkin mutations</article-title><source>Cell Rep.</source><year>2017</year><volume>19</volume><fpage>1033</fpage><lpage>1044</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.04.023</pub-id><?supplied-pmid 28467897?><pub-id pub-id-type="pmid">28467897</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laperle</surname><given-names>AH</given-names></name><etal/></person-group><article-title>iPSC modeling of young-onset Parkinson's disease reveals a molecular signature of disease and novel therapeutic candidates</article-title><source>Nat. Med.</source><year>2020</year><volume>26</volume><fpage>289</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0739-1</pub-id><?supplied-pmid 31988461?><pub-id pub-id-type="pmid">31988461</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>TB</given-names></name><etal/></person-group><article-title>alpha-Synuclein gene duplication is present in sporadic Parkinson disease</article-title><source>Neurology</source><year>2008</year><volume>70</volume><fpage>43</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000271080.53272.c7</pub-id><?supplied-pmid 17625105?><pub-id pub-id-type="pmid">17625105</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bentley</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Pipeline to gene discovery&#x02014;analysing familial Parkinsonism in the Queensland Parkinson's Project</article-title><source>Parkinsonism Relat. Disord.</source><year>2018</year><volume>49</volume><fpage>34</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2017.12.033</pub-id><?supplied-pmid 29329938?><pub-id pub-id-type="pmid">29329938</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanckenberg</surname><given-names>J</given-names></name><name><surname>Ntsapi</surname><given-names>C</given-names></name><name><surname>Carr</surname><given-names>JA</given-names></name><name><surname>Bardien</surname><given-names>S</given-names></name></person-group><article-title>EIF4G1 R1205H and VPS35 D620N mutations are rare in Parkinson's disease from South Africa</article-title><source>Neurobiol. Aging</source><year>2014</year><volume>35</volume><fpage>445.e441</fpage><lpage>445.e443</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2013.08.023</pub-id><pub-id pub-id-type="pmid">24080171</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brueggemann</surname><given-names>N</given-names></name><etal/></person-group><article-title>Re: Alpha-synuclein gene duplication is present in sporadic Parkinson disease</article-title><source>Neurology</source><year>2008</year><volume>71</volume><fpage>1294</fpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000338439.00992.c7</pub-id><?supplied-pmid 18852448?><pub-id pub-id-type="pmid">18852448</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camacho</surname><given-names>JLG</given-names></name><etal/></person-group><article-title>High frequency of Parkin exon rearrangements in Mexican-mestizo patients with early-onset Parkinson's disease</article-title><source>Mov. Disord.</source><year>2012</year><volume>27</volume><fpage>1047</fpage><lpage>1051</lpage><pub-id pub-id-type="doi">10.1002/mds.25030</pub-id><pub-id pub-id-type="pmid">22777964</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>VPS35 Asp620Asn and EIF4G1 Arg1205His mutations are rare in Parkinson disease from Southwest China</article-title><source>Neurobiol. Aging</source><year>2013</year><volume>34</volume><fpage>1709.e1707</fpage><lpage>1709.e1708</lpage></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Djarmati</surname><given-names>A</given-names></name><etal/></person-group><article-title>ATP13A2 variants in early-onset Parkinson's disease patients and controls</article-title><source>Mov. Disord.</source><year>2009</year><volume>24</volume><fpage>2104</fpage><lpage>2111</lpage><pub-id pub-id-type="doi">10.1002/mds.22728</pub-id><?supplied-pmid 19705361?><pub-id pub-id-type="pmid">19705361</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Djarmati</surname><given-names>A</given-names></name><etal/></person-group><article-title>Detection of Parkin(PARK2) and DJ1(PARK7) mutations in early-onset Parkinson disease: Parkinmutation frequency depends on ethnic origin of patients</article-title><source>Hum. Mutat.</source><year>2004</year><volume>23</volume><fpage>525</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1002/humu.9240</pub-id><?supplied-pmid 15108293?><pub-id pub-id-type="pmid">15108293</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erer</surname><given-names>S</given-names></name><etal/></person-group><article-title>Mutation analysis of the PARKIN, PINK1, DJ1, and SNCA genes in Turkish early-onset Parkinson's patients and genotype-phenotype correlations</article-title><source>Clin. Neurol. Neurosurg.</source><year>2016</year><volume>148</volume><fpage>147</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/j.clineuro.2016.07.005</pub-id><?supplied-pmid 27455133?><pub-id pub-id-type="pmid">27455133</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiala</surname><given-names>O</given-names></name><etal/></person-group><article-title>Parkin (PARK 2) mutations are rare in Czech patients with early-onset Parkinson's disease</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><fpage>e107585</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0107585</pub-id><?supplied-pmid 25238391?><pub-id pub-id-type="pmid">25238391</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>JF</given-names></name><etal/></person-group><article-title>VPS35 gene variants are not associated with Parkinson's disease in the mainland Chinese population</article-title><source>Parkinsonism Relat. Disord.</source><year>2012</year><volume>18</volume><fpage>983</fpage><lpage>985</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2012.05.002</pub-id><?supplied-pmid 22673036?><pub-id pub-id-type="pmid">22673036</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Healy</surname><given-names>DG</given-names></name><etal/></person-group><article-title>Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study</article-title><source>Lancet Neurol.</source><year>2008</year><volume>7</volume><fpage>583</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(08)70117-0</pub-id><?supplied-pmid 18539534?><pub-id pub-id-type="pmid">18539534</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hedrich</surname><given-names>K</given-names></name><etal/></person-group><article-title>DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease</article-title><source>Neurology</source><year>2004</year><volume>62</volume><fpage>389</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000113022.51739.88</pub-id><?supplied-pmid 14872018?><pub-id pub-id-type="pmid">14872018</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>NL</given-names></name><etal/></person-group><article-title>Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data</article-title><source>Brain</source><year>2005</year><volume>128</volume><fpage>2786</fpage><lpage>2796</lpage><pub-id pub-id-type="doi">10.1093/brain/awh667</pub-id><?supplied-pmid 16272164?><pub-id pub-id-type="pmid">16272164</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>C</given-names></name><etal/></person-group><article-title>PINK1, Parkin, and DJ-1 mutations in Italian patients with early-onset parkinsonism</article-title><source>Eur. J. Hum. Genet.</source><year>2005</year><volume>13</volume><fpage>1086</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.1038/sj.ejhg.5201455</pub-id><?supplied-pmid 15970950?><pub-id pub-id-type="pmid">15970950</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>KR</given-names></name><etal/></person-group><article-title>Frequency of the D620N mutation in VPS35 in Parkinson disease</article-title><source>Arch. Neurol.</source><year>2012</year><volume>69</volume><fpage>1360</fpage><lpage>1364</lpage><pub-id pub-id-type="doi">10.1001/archneurol.2011.3367</pub-id><?supplied-pmid 22801713?><pub-id pub-id-type="pmid">22801713</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Longo</surname><given-names>GS</given-names></name><etal/></person-group><article-title>Alpha-synuclein A53T mutation is not frequent on a sample of Brazilian Parkinson's disease patients</article-title><source>Arq. Neuropsiquiatr.</source><year>2015</year><volume>73</volume><fpage>506</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1590/0004-282X20150032</pub-id><?supplied-pmid 26083886?><pub-id pub-id-type="pmid">26083886</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macedo</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Genotypic and phenotypic characteristics of Dutch patients with early onset Parkinson's disease</article-title><source>Mov. Disord.</source><year>2009</year><volume>24</volume><fpage>196</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1002/mds.22287</pub-id><?supplied-pmid 18973254?><pub-id pub-id-type="pmid">18973254</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mata</surname><given-names>IF</given-names></name><etal/></person-group><article-title>Lrrk2 pathogenic substitutions in Parkinson's disease</article-title><source>Neurogenetics</source><year>2005</year><volume>6</volume><fpage>171</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1007/s10048-005-0005-1</pub-id><?supplied-pmid 16172858?><pub-id pub-id-type="pmid">16172858</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mellick</surname><given-names>GD</given-names></name><etal/></person-group><article-title>Screening PARK genes for mutations in early-onset Parkinson's disease patients from Queensland, Australia</article-title><source>Parkinsonism Relat. Disord.</source><year>2009</year><volume>15</volume><fpage>105</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2007.11.016</pub-id><?supplied-pmid 18486522?><pub-id pub-id-type="pmid">18486522</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moura</surname><given-names>KC</given-names></name><etal/></person-group><article-title>Exon dosage variations in Brazilian patients with Parkinson's disease: analysis of SNCA, PARKIN, PINK1 and DJ-1 genes</article-title><source>Dis. Markers</source><year>2012</year><volume>32</volume><fpage>173</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1155/2012/218642</pub-id><?supplied-pmid 22377733?><pub-id pub-id-type="pmid">22377733</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>WC</given-names></name><etal/></person-group><article-title>Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease</article-title><source>Lancet</source><year>2005</year><volume>365</volume><fpage>410</fpage><lpage>412</lpage><?supplied-pmid 15680455?><pub-id pub-id-type="pmid">15680455</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>M</given-names></name><etal/></person-group><article-title>A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants</article-title><source>J. Med Genet.</source><year>2012</year><volume>49</volume><fpage>721</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1136/jmedgenet-2012-101155</pub-id><?supplied-pmid 3488700?><pub-id pub-id-type="pmid">23125461</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheerin</surname><given-names>UM</given-names></name><etal/></person-group><article-title>Screening for VPS35 mutations in Parkinson's disease</article-title><source>Neurobiol. Aging</source><year>2012</year><volume>33</volume><fpage>838 e831</fpage><lpage>835</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2011.10.032</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sudhaman</surname><given-names>S</given-names></name><etal/></person-group><article-title>VPS35 and EIF4G1 mutations are rare in Parkinson's disease among Indians</article-title><source>Neurobiol. Aging</source><year>2013</year><volume>34</volume><fpage>2442.e2441</fpage><lpage>2442.e2443</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2013.04.025</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valente</surname><given-names>EM</given-names></name><etal/></person-group><article-title>PINK1 mutations are associated with sporadic early-onset parkinsonism</article-title><source>Ann. Neurol.</source><year>2004</year><volume>56</volume><fpage>336</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1002/ana.20256</pub-id><?supplied-pmid 15349860?><pub-id pub-id-type="pmid">15349860</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vilarino-Guell</surname><given-names>C</given-names></name><etal/></person-group><article-title>VPS35 mutations in Parkinson disease</article-title><source>Am. J. Hum. Genet.</source><year>2011</year><volume>89</volume><fpage>162</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2011.06.001</pub-id><?supplied-pmid 21763482?><pub-id pub-id-type="pmid">21763482</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>YR</given-names></name><etal/></person-group><article-title>Genetic analysis of Parkin in early onset Parkinson's disease (PD): novel intron 9&#x02009;g&#x0003e;&#x02009;a single nucleotide polymorphism and risk of Taiwanese PD</article-title><source>Am. J. Med. Genet. B Neuropsychiatr. Genet.</source><year>2010</year><volume>153B</volume><fpage>229</fpage><lpage>234</lpage><?supplied-pmid 19475582?><pub-id pub-id-type="pmid">19475582</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimprich</surname><given-names>A</given-names></name><etal/></person-group><article-title>A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease</article-title><source>Am. J. Hum. Genet.</source><year>2011</year><volume>89</volume><fpage>168</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2011.06.008</pub-id><?supplied-pmid 21763483?><pub-id pub-id-type="pmid">21763483</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abou-Sleiman</surname><given-names>PM</given-names></name><name><surname>Healy</surname><given-names>DG</given-names></name><name><surname>Quinn</surname><given-names>N</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name><name><surname>Wood</surname><given-names>NW</given-names></name></person-group><article-title>The role of pathogenic DJ-1 mutations in Parkinson's disease</article-title><source>Ann. Neurol.</source><year>2003</year><volume>54</volume><fpage>283</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1002/ana.10675</pub-id><?supplied-pmid 12953260?><pub-id pub-id-type="pmid">12953260</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alcalay</surname><given-names>RN</given-names></name><etal/></person-group><article-title>Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study</article-title><source>Arch. Neurol.</source><year>2010</year><volume>67</volume><fpage>1116</fpage><lpage>1122</lpage><pub-id pub-id-type="doi">10.1001/archneurol.2010.194</pub-id><?supplied-pmid 20837857?><pub-id pub-id-type="pmid">20837857</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alcalay</surname><given-names>RN</given-names></name><etal/></person-group><article-title>SMPD1 mutations, activity, and alpha-synuclein accumulation in Parkinson's disease</article-title><source>Mov. Disord.</source><year>2019</year><volume>34</volume><fpage>526</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1002/mds.27642</pub-id><?supplied-pmid 30788890?><pub-id pub-id-type="pmid">30788890</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anwarullah</surname></name><etal/></person-group><article-title>Absence of SNCA polymorphisms in Pakistani Parkinsons disease patients</article-title><source>Jpma. J. Pak. Med. Assoc.</source><year>2017</year><volume>67</volume><fpage>1512</fpage><lpage>1516</lpage><pub-id pub-id-type="pmid">28955066</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hattori</surname><given-names>N</given-names></name><etal/></person-group><article-title>Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals</article-title><source>Ann. Neurol.</source><year>1998</year><volume>44</volume><fpage>935</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.1002/ana.410440612</pub-id><?supplied-pmid 9851438?><pub-id pub-id-type="pmid">9851438</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>J</given-names></name><etal/></person-group><article-title>SNCA multiplication is not a common cause of Parkinson disease or dementia with Lewy bodies</article-title><source>Neurology</source><year>2004</year><volume>63</volume><fpage>554</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000133401.09043.44</pub-id><?supplied-pmid 15304594?><pub-id pub-id-type="pmid">15304594</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucking</surname><given-names>CB</given-names></name><etal/></person-group><article-title>Association between early-onset Parkinson's disease and mutations in the parkin gene</article-title><source>N. Engl. J. Med.</source><year>2000</year><volume>342</volume><fpage>1560</fpage><lpage>1567</lpage><pub-id pub-id-type="doi">10.1056/NEJM200005253422103</pub-id><?supplied-pmid 10824074?><pub-id pub-id-type="pmid">10824074</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogaeva</surname><given-names>E</given-names></name><etal/></person-group><article-title>Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease</article-title><source>Arch. Neurol.</source><year>2004</year><volume>61</volume><fpage>1898</fpage><lpage>1904</lpage><pub-id pub-id-type="doi">10.1001/archneur.61.12.1898</pub-id><?supplied-pmid 15596610?><pub-id pub-id-type="pmid">15596610</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sim&#x000f3;n-S&#x000e1;nchez</surname><given-names>J</given-names></name><etal/></person-group><article-title>Genome-wide association study confirms extant PD risk loci among the Dutch</article-title><source>Eur. J. Hum. Genet.</source><year>2011</year><volume>19</volume><fpage>655</fpage><pub-id pub-id-type="doi">10.1038/ejhg.2010.254</pub-id><?supplied-pmid 21248740?><pub-id pub-id-type="pmid">21248740</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Marco</surname><given-names>EV</given-names></name><etal/></person-group><article-title>DJ-1 is a Parkinson's disease susceptibility gene in southern Italy</article-title><source>Clin. Genet.</source><year>2010</year><volume>77</volume><fpage>183</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1111/j.1399-0004.2009.01310.x</pub-id><pub-id pub-id-type="pmid">19968671</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Jankovic</surname><given-names>J</given-names></name></person-group><article-title>The EIF4G1 gene and Parkinson's disease</article-title><source>Acta Neurologica Scandinavica</source><year>2015</year><volume>132</volume><fpage>73</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1111/ane.12397</pub-id><pub-id pub-id-type="pmid">25765080</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foo</surname><given-names>JN</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>E-K</given-names></name></person-group><article-title>CHCHD2 and Parkinson's disease</article-title><source>Lancet Neurol.</source><year>2015</year><volume>14</volume><fpage>681</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(15)00098-8</pub-id><pub-id pub-id-type="pmid">26067114</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Funayama</surname><given-names>M</given-names></name><etal/></person-group><article-title>Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population</article-title><source>Neuroreport</source><year>2007</year><volume>18</volume><fpage>273</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1097/WNR.0b013e32801254b6</pub-id><pub-id pub-id-type="pmid">17314670</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Funayama</surname><given-names>M</given-names></name><etal/></person-group><article-title>CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study</article-title><source>Lancet Neurol.</source><year>2015</year><volume>14</volume><fpage>274</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(14)70266-2</pub-id><pub-id pub-id-type="pmid">25662902</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f3;mez-Garre</surname><given-names>P</given-names></name><etal/></person-group><article-title>Systematic mutational analysis of FBXO7 in a Parkinson's disease population from southern Spain</article-title><source>Neurobiol. Aging</source><year>2014</year><volume>35</volume><fpage>727.e725</fpage><lpage>727.e727</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2013.09.011</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huttenlocher</surname><given-names>J</given-names></name><etal/></person-group><article-title>Heterozygote carriers for CNVs in PARK2 are at increased risk of Parkinson's disease</article-title><source>Hum. Mol. Genet.</source><year>2015</year><volume>24</volume><fpage>5637</fpage><lpage>5643</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddv277</pub-id><pub-id pub-id-type="pmid">26188007</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kay</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients</article-title><source>Ann. Neurol.</source><year>2007</year><volume>61</volume><fpage>47</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1002/ana.21039</pub-id><pub-id pub-id-type="pmid">17187375</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kr&#x000fc;ger</surname><given-names>R</given-names></name><etal/></person-group><article-title>A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease</article-title><source>Neurobiol. aging</source><year>2011</year><volume>32</volume><fpage>548.e549</fpage><lpage>548.e545.548E518</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2009.11.021</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maraganore</surname><given-names>DM</given-names></name><etal/></person-group><article-title>High-resolution whole-genome association study of Parkinson disease</article-title><source>Am. J. Hum. Genet.</source><year>2005</year><volume>77</volume><fpage>685</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1086/496902</pub-id><?supplied-pmid 1271381?><pub-id pub-id-type="pmid">16252231</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nalls</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease</article-title><source>Nat. Genet.</source><year>2014</year><volume>46</volume><fpage>989</fpage><pub-id pub-id-type="doi">10.1038/ng.3043</pub-id><?supplied-pmid 4146673?><pub-id pub-id-type="pmid">25064009</pub-id></element-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pihlstr&#x000f8;m</surname><given-names>L</given-names></name><etal/></person-group><article-title>Supportive evidence for 11 loci from genome-wide association studies in Parkinson's disease</article-title><source>Neurobiol. Aging</source><year>2013</year><volume>34</volume><fpage>1708.e1707</fpage><lpage>1708.e1713</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2012.10.019</pub-id></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ran</surname><given-names>C</given-names></name><etal/></person-group><article-title>Strong association between glucocerebrosidase mutations and Parkinson's disease in Sweden</article-title><source>Neurobiol. Aging</source><year>2016</year><volume>45</volume><fpage>212.e215</fpage><lpage>212.e211</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2016.04.022</pub-id></element-citation></ref><ref id="CR144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>OA</given-names></name><etal/></person-group><article-title>Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease</article-title><source>Ann. Neurol.</source><year>2008</year><volume>64</volume><fpage>88</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1002/ana.21405</pub-id><pub-id pub-id-type="pmid">18412265</pub-id></element-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semenova</surname><given-names>EV</given-names></name><etal/></person-group><article-title>Analysis of PARK2 gene exon rearrangements in Russian patients with sporadic Parkinson's disease</article-title><source>Mov. Disord.</source><year>2012</year><volume>27</volume><fpage>139</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1002/mds.23901</pub-id><pub-id pub-id-type="pmid">21915905</pub-id></element-citation></ref><ref id="CR146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sidransky</surname><given-names>E</given-names></name><name><surname>Lopez</surname><given-names>G</given-names></name></person-group><article-title>The link between the GBA gene and parkinsonism</article-title><source>Lancet Neurol.</source><year>2012</year><volume>11</volume><fpage>986</fpage><lpage>998</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(12)70190-4</pub-id><?supplied-pmid 4141416?><pub-id pub-id-type="pmid">23079555</pub-id></element-citation></ref><ref id="CR147"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The contribution of GIGYF2 to Parkinson's disease: a meta-analysis</article-title><source>Neurological Sci. : Off. J. Ital. Neurological Soc. Ital. Soc. Clin. Neurophysiol.</source><year>2015</year><volume>36</volume><fpage>2073</fpage><lpage>2079</lpage><pub-id pub-id-type="doi">10.1007/s10072-015-2316-9</pub-id></element-citation></ref><ref id="CR148"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puschmann</surname><given-names>A</given-names></name><etal/></person-group><article-title>Heterozygous PINK1 p.G411S increases risk of Parkinson's disease via a dominant-negative mechanism</article-title><source>Brain</source><year>2017</year><volume>140</volume><fpage>98</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1093/brain/aww261</pub-id><pub-id pub-id-type="pmid">27807026</pub-id></element-citation></ref><ref id="CR149"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacArthur</surname><given-names>J</given-names></name><etal/></person-group><article-title>The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog)</article-title><source>Nucleic Acids Res.</source><year>2017</year><volume>45</volume><fpage>D896</fpage><lpage>D901</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw1133</pub-id><pub-id pub-id-type="pmid">27899670</pub-id></element-citation></ref><ref id="CR150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>WK</given-names></name><etal/></person-group><article-title>Genetic complexity and Parkinson's disease. Deane Laboratory Parkinson Disease Research Group</article-title><source>Science</source><year>1997</year><volume>277</volume><fpage>387</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1126/science.277.5324.387</pub-id><pub-id pub-id-type="pmid">9518366</pub-id></element-citation></ref><ref id="CR151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shulman</surname><given-names>JM</given-names></name><name><surname>De Jager</surname><given-names>PL</given-names></name><name><surname>Feany</surname><given-names>MB</given-names></name></person-group><article-title>Parkinson&#x02019;s disease: genetics and pathogenesis</article-title><source>Annu. Rev. Pathol.</source><year>2011</year><volume>6</volume><fpage>193</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1146/annurev-pathol-011110-130242</pub-id><pub-id pub-id-type="pmid">21034221</pub-id></element-citation></ref><ref id="CR152"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adler</surname><given-names>CH</given-names></name></person-group><article-title>Differential diagnosis of Parkinson's disease</article-title><source>Med Clin. North Am.</source><year>1999</year><volume>83</volume><fpage>349</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1016/S0025-7125(05)70108-5</pub-id><pub-id pub-id-type="pmid">10093582</pub-id></element-citation></ref><ref id="CR153"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langston</surname><given-names>JW</given-names></name><name><surname>Ballard</surname><given-names>P</given-names></name><name><surname>Tetrud</surname><given-names>JW</given-names></name><name><surname>Irwin</surname><given-names>I</given-names></name></person-group><article-title>Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis</article-title><source>Science</source><year>1983</year><volume>219</volume><fpage>979</fpage><lpage>980</lpage><pub-id pub-id-type="doi">10.1126/science.6823561</pub-id><pub-id pub-id-type="pmid">6823561</pub-id></element-citation></ref><ref id="CR154"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>TP</given-names></name><name><surname>Rumsby</surname><given-names>PC</given-names></name><name><surname>Capleton</surname><given-names>AC</given-names></name><name><surname>Rushton</surname><given-names>L</given-names></name><name><surname>Levy</surname><given-names>LS</given-names></name></person-group><article-title>Pesticides and Parkinson's disease-is there a link?</article-title><source>Environ. Health Perspect.</source><year>2006</year><volume>114</volume><fpage>156</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1289/ehp.8095</pub-id><pub-id pub-id-type="pmid">16451848</pub-id></element-citation></ref><ref id="CR155"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reeve</surname><given-names>A</given-names></name><name><surname>Simcox</surname><given-names>E</given-names></name><name><surname>Turnbull</surname><given-names>D</given-names></name></person-group><article-title>Ageing and Parkinson's disease: why is advancing age the biggest risk factor?</article-title><source>Ageing Res Rev.</source><year>2014</year><volume>14</volume><fpage>19</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.arr.2014.01.004</pub-id><?supplied-pmid 3989046?><pub-id pub-id-type="pmid">24503004</pub-id></element-citation></ref><ref id="CR156"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>G</given-names></name></person-group><article-title>The relationship of Parkinson disease with aging</article-title><source>Arch. Neurol.</source><year>2007</year><volume>64</volume><fpage>1242</fpage><lpage>1246</lpage><pub-id pub-id-type="doi">10.1001/archneur.64.9.1242</pub-id><pub-id pub-id-type="pmid">17846263</pub-id></element-citation></ref><ref id="CR157"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Autere</surname><given-names>JM</given-names></name><name><surname>Moilanen</surname><given-names>JS</given-names></name><name><surname>Myllyla</surname><given-names>VV</given-names></name><name><surname>Majamaa</surname><given-names>K</given-names></name></person-group><article-title>Familial aggregation of Parkinson's disease in a Finnish population</article-title><source>J. Neurol. Neurosurg. psychiatry</source><year>2000</year><volume>69</volume><fpage>107</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1136/jnnp.69.1.107</pub-id><?supplied-pmid 1737008?><pub-id pub-id-type="pmid">10864614</pub-id></element-citation></ref><ref id="CR158"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonifati</surname><given-names>V</given-names></name><name><surname>Fabrizio</surname><given-names>E</given-names></name><name><surname>Vanacore</surname><given-names>N</given-names></name><name><surname>De Mari</surname><given-names>M</given-names></name><name><surname>Meco</surname><given-names>G</given-names></name></person-group><article-title>Familial Parkinson's disease: a clinical genetic analysis</article-title><source>Can. J. Neurol Sci.</source><year>1995</year><volume>22</volume><fpage>272</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1017/S0317167100039469</pub-id><pub-id pub-id-type="pmid">8599769</pub-id></element-citation></ref><ref id="CR159"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elbaz</surname><given-names>A</given-names></name><etal/></person-group><article-title>Familial aggregation of Parkinson's disease: a population-based case-control study in Europe. EUROPARKINSON Study Group</article-title><source>Neurology</source><year>1999</year><volume>52</volume><fpage>1876</fpage><lpage>1882</lpage><pub-id pub-id-type="doi">10.1212/WNL.52.9.1876</pub-id><pub-id pub-id-type="pmid">10371537</pub-id></element-citation></ref><ref id="CR160"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurz</surname><given-names>M</given-names></name><name><surname>Alves</surname><given-names>G</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Larsen</surname><given-names>JP</given-names></name></person-group><article-title>Familial Parkinson's disease: a community-based study</article-title><source>Eur. J. Neurol.</source><year>2003</year><volume>10</volume><fpage>159</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1046/j.1468-1331.2003.00532.x</pub-id><pub-id pub-id-type="pmid">12603291</pub-id></element-citation></ref><ref id="CR161"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linder</surname><given-names>J</given-names></name><name><surname>Stenlund</surname><given-names>H</given-names></name><name><surname>Forsgren</surname><given-names>L</given-names></name></person-group><article-title>Incidence of Parkinson's disease and parkinsonism in northern Sweden: a population-based study</article-title><source>Mov. Disord.</source><year>2010</year><volume>25</volume><fpage>341</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1002/mds.22987</pub-id><pub-id pub-id-type="pmid">20108376</pub-id></element-citation></ref><ref id="CR162"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonnell</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Complex segregation analysis of Parkinson's disease: the Mayo Clinic Family Study</article-title><source>Ann. Neurol.</source><year>2006</year><volume>59</volume><fpage>788</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1002/ana.20844</pub-id><?supplied-pmid 16634030?><pub-id pub-id-type="pmid">16634030</pub-id></element-citation></ref><ref id="CR163"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Payami</surname><given-names>H</given-names></name><name><surname>Larsen</surname><given-names>K</given-names></name><name><surname>Bernard</surname><given-names>S</given-names></name><name><surname>Nutt</surname><given-names>J</given-names></name></person-group><article-title>Increased risk of Parkinson's disease in parents and siblings of patients</article-title><source>Ann. Neurol.</source><year>1994</year><volume>36</volume><fpage>659</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1002/ana.410360417</pub-id><?supplied-pmid 7605419?><pub-id pub-id-type="pmid">7605419</pub-id></element-citation></ref><ref id="CR164"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petersen</surname><given-names>MS</given-names></name><name><surname>Bech</surname><given-names>S</given-names></name><name><surname>Nosova</surname><given-names>E</given-names></name><name><surname>Aasly</surname><given-names>J</given-names></name><name><surname>Farrer</surname><given-names>MJ</given-names></name></person-group><article-title>Familial aggregation of Parkinson's disease in the Faroe Islands</article-title><source>Mov. Disord.</source><year>2015</year><volume>30</volume><fpage>538</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1002/mds.26132</pub-id><pub-id pub-id-type="pmid">25600277</pub-id></element-citation></ref><ref id="CR165"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shino</surname><given-names>MY</given-names></name><etal/></person-group><article-title>Familial aggregation of Parkinson's disease in a multiethnic community-based case-control study</article-title><source>Mov. Disord. Off. J. Mov. Disord. Soc.</source><year>2010</year><volume>25</volume><fpage>2587</fpage><lpage>2594</lpage><pub-id pub-id-type="doi">10.1002/mds.23361</pub-id></element-citation></ref><ref id="CR166"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uitti</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>"Familial Parkinson's disease"-a case-control study of families</article-title><source>Can. J. Neurol. Sci.</source><year>1997</year><volume>24</volume><fpage>127</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1017/S0317167100021454</pub-id><pub-id pub-id-type="pmid">9164689</pub-id></element-citation></ref><ref id="CR167"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olgiati</surname><given-names>S</given-names></name><etal/></person-group><article-title>DNAJC6 mutations associated with early-onset Parkinson's disease</article-title><source>Ann. Neurol.</source><year>2016</year><volume>79</volume><fpage>244</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1002/ana.24553</pub-id><pub-id pub-id-type="pmid">26528954</pub-id></element-citation></ref><ref id="CR168"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamura</surname><given-names>Y</given-names></name></person-group><article-title>The long journey to the discovery of PARK2: the 50th anniversary of Japanese Society of Neuropathology</article-title><source>Neuropathol. Off. J. Jpn. Soc. Neuropathol.</source><year>2010</year><volume>30</volume><fpage>495</fpage><lpage>500</lpage></element-citation></ref><ref id="CR169"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Funayama</surname><given-names>M</given-names></name><etal/></person-group><article-title>A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1</article-title><source>Ann. Neurol.</source><year>2002</year><volume>51</volume><fpage>296</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1002/ana.10113</pub-id><pub-id pub-id-type="pmid">11891824</pub-id></element-citation></ref><ref id="CR170"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonifati</surname><given-names>V</given-names></name><etal/></person-group><article-title>Mutations in the DJ-1 gene associated with autosomal recessive early-onset Parkinsonism</article-title><source>Science</source><year>2003</year><volume>299</volume><fpage>256</fpage><pub-id pub-id-type="doi">10.1126/science.1077209</pub-id><pub-id pub-id-type="pmid">12446870</pub-id></element-citation></ref><ref id="CR171"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gandhi</surname><given-names>S</given-names></name><etal/></person-group><article-title>PINK1 protein in normal human brain and Parkinson's disease</article-title><source>Brain</source><year>2006</year><volume>129</volume><fpage>1720</fpage><lpage>1731</lpage><pub-id pub-id-type="doi">10.1093/brain/awl114</pub-id><pub-id pub-id-type="pmid">16702191</pub-id></element-citation></ref><ref id="CR172"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Fonzo</surname><given-names>A</given-names></name><etal/></person-group><article-title>ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease</article-title><source>Neurology</source><year>2007</year><volume>68</volume><fpage>1557</fpage><lpage>1562</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000260963.08711.08</pub-id><pub-id pub-id-type="pmid">17485642</pub-id></element-citation></ref><ref id="CR173"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edvardson</surname><given-names>S</given-names></name><etal/></person-group><article-title>A deleterious mutation in DNAJC6 encoding the neuronal-specific clathrin-uncoating co-chaperone auxilin, is associated with juvenile parkinsonism</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><fpage>e36458</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0036458</pub-id><?supplied-pmid 3341348?><pub-id pub-id-type="pmid">22563501</pub-id></element-citation></ref><ref id="CR174"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burchell</surname><given-names>VS</given-names></name><etal/></person-group><article-title>The Parkinson's disease-linked proteins Fbxo7 and Parkin interact to mediate mitophagy</article-title><source>Nat. Neurosci.</source><year>2013</year><volume>16</volume><fpage>1257</fpage><pub-id pub-id-type="doi">10.1038/nn.3489</pub-id><pub-id pub-id-type="pmid">23933751</pub-id></element-citation></ref><ref id="CR175"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quadri</surname><given-names>M</given-names></name><etal/></person-group><article-title>Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset Parkinsonism</article-title><source>Hum. Mutat.</source><year>2013</year><volume>34</volume><fpage>1208</fpage><lpage>1215</lpage><pub-id pub-id-type="doi">10.1002/humu.22373</pub-id><?supplied-pmid 23804577?><pub-id pub-id-type="pmid">23804577</pub-id></element-citation></ref><ref id="CR176"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>C-S</given-names></name><etal/></person-group><article-title>PLA2G6 mutations in PARK14-linked young-onset parkinsonism and sporadic Parkinson's disease</article-title><source>Am. J. Med. Genet. Part B Neuropsychiatr. Genet.</source><year>2012</year><volume>159B</volume><fpage>183</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1002/ajmg.b.32012</pub-id></element-citation></ref><ref id="CR177"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strauss</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease</article-title><source>Hum. Mol. Genet.</source><year>2005</year><volume>14</volume><fpage>2099</fpage><lpage>2111</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddi215</pub-id><?supplied-pmid 15961413?><pub-id pub-id-type="pmid">15961413</pub-id></element-citation></ref><ref id="CR178"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schormair</surname><given-names>B</given-names></name><etal/></person-group><article-title>Diagnostic exome sequencing in early-onset Parkinson's disease confirms VPS13C as a rare cause of autosomal-recessive Parkinson's disease</article-title><source>Clin. Genet.</source><year>2018</year><volume>93</volume><fpage>603</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.1111/cge.13124</pub-id><?supplied-pmid 28862745?><pub-id pub-id-type="pmid">28862745</pub-id></element-citation></ref><ref id="CR179"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keller</surname><given-names>MF</given-names></name><etal/></person-group><article-title>Using genome-wide complex trait analysis to quantify &#x02018;missing heritability&#x02019; in Parkinson's disease</article-title><source>Hum. Mol. Genet.</source><year>2012</year><volume>21</volume><fpage>4996</fpage><lpage>5009</lpage><pub-id pub-id-type="doi">10.1093/hmg/dds335</pub-id><?supplied-pmid 22892372?><pub-id pub-id-type="pmid">22892372</pub-id></element-citation></ref><ref id="CR180"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>International Parkinson's Disease Genomics ConsortiumWellcome Trust Case Control Consortium 2</collab></person-group><article-title>A two-stage meta-analysis identifies several new loci for Parkinson's disease</article-title><source>PLoS Genet.</source><year>2011</year><volume>7</volume><fpage>e1002142</fpage><lpage>e1002142</lpage><pub-id pub-id-type="doi">10.1371/journal.pgen.1002142</pub-id><pub-id pub-id-type="pmid">21738488</pub-id></element-citation></ref><ref id="CR181"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamanaka</surname><given-names>S</given-names></name></person-group><article-title>Strategies and new developments in the generation of patient-specific pluripotent stem cells</article-title><source>Cell Stem Cell</source><year>2007</year><volume>1</volume><fpage>39</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2007.05.012</pub-id><?supplied-pmid 18371333?><pub-id pub-id-type="pmid">18371333</pub-id></element-citation></ref><ref id="CR182"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Yamanaka</surname><given-names>S</given-names></name></person-group><article-title>Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors</article-title><source>Cell</source><year>2006</year><volume>126</volume><fpage>663</fpage><lpage>676</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.07.024</pub-id><?supplied-pmid 16904174?><pub-id pub-id-type="pmid">16904174</pub-id></element-citation></ref><ref id="CR183"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Induction of pluripotent stem cells from adult human fibroblasts by defined factors</article-title><source>Cell</source><year>2007</year><volume>131</volume><fpage>861</fpage><lpage>872</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.11.019</pub-id><?supplied-pmid 18035408?><pub-id pub-id-type="pmid">18035408</pub-id></element-citation></ref><ref id="CR184"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchetto</surname><given-names>MC</given-names></name><name><surname>Brennand</surname><given-names>KJ</given-names></name><name><surname>Boyer</surname><given-names>LF</given-names></name><name><surname>Gage</surname><given-names>FH</given-names></name></person-group><article-title>Induced pluripotent stem cells (iPSCs) and neurological disease modeling: progress and promises</article-title><source>Hum. Mol. Genet.</source><year>2011</year><volume>20</volume><fpage>R109</fpage><lpage>R115</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddr336</pub-id><?supplied-pmid 21828073?><pub-id pub-id-type="pmid">21828073</pub-id></element-citation></ref><ref id="CR185"><label>185.</label><mixed-citation publication-type="other">Bardy, C., Greenberg, Z., Perry, S. W. &#x00026; Licinio, J. in <italic>Personalized Psychiatry</italic> (ed Baune, B. T.) 127&#x02013;146 (Academic Press, 2020).</mixed-citation></ref><ref id="CR186"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burkhardt</surname><given-names>MF</given-names></name><etal/></person-group><article-title>A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells</article-title><source>Mol. Cell Neurosci.</source><year>2013</year><volume>56</volume><fpage>355</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1016/j.mcn.2013.07.007</pub-id><?supplied-pmid 23891805?><pub-id pub-id-type="pmid">23891805</pub-id></element-citation></ref><ref id="CR187"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Israel</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Probing sporadic and familial Alzheimer&#x02019;s disease using induced pluripotent stem cells</article-title><source>Nature</source><year>2012</year><volume>482</volume><fpage>216</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1038/nature10821</pub-id><?supplied-pmid 22278060?><pub-id pub-id-type="pmid">22278060</pub-id></element-citation></ref><ref id="CR188"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutherland</surname><given-names>GT</given-names></name><etal/></person-group><article-title>A cross-study transcriptional analysis of Parkinson's disease</article-title><source>PLOS ONE</source><year>2009</year><volume>4</volume><fpage>e4955</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0004955</pub-id><?supplied-pmid 19305504?><pub-id pub-id-type="pmid">19305504</pub-id></element-citation></ref><ref id="CR189"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoekstra</surname><given-names>SD</given-names></name><name><surname>Stringer</surname><given-names>S</given-names></name><name><surname>Heine</surname><given-names>VM</given-names></name><name><surname>Posthuma</surname><given-names>D</given-names></name></person-group><article-title>Genetically-informed patient selection for iPSC studies of complex diseases may aid in reducing cellular heterogeneity</article-title><source>Front. Cell. Neurosci.</source><year>2017</year><volume>11</volume><fpage>164</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.3389/fncel.2017.00164</pub-id><?supplied-pmid 28659762?><pub-id pub-id-type="pmid">28659762</pub-id></element-citation></ref><ref id="CR190"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soldner</surname><given-names>F</given-names></name><etal/></person-group><article-title>Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors</article-title><source>Cell</source><year>2009</year><volume>136</volume><fpage>964</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.02.013</pub-id><?supplied-pmid 19269371?><pub-id pub-id-type="pmid">19269371</pub-id></element-citation></ref><ref id="CR191"><label>191.</label><mixed-citation publication-type="other">Byrne, S. M., Mali, P. &#x00026; Church, G. M. in <italic>Methods in Enzymology</italic>, Vol. 546 (eds Doudna J. A. &#x00026; Sontheimer E. J.) 119&#x02013;138 (Academic Press, 2014).</mixed-citation></ref><ref id="CR192"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>NY</given-names></name><name><surname>Liu</surname><given-names>G-H</given-names></name><name><surname>Izpisua Belmonte</surname><given-names>JC</given-names></name></person-group><article-title>A cut above the rest: targeted genome editing technologies in human pluripotent stem cells</article-title><source>J. Biol. Chem.</source><year>2014</year><volume>289</volume><fpage>4594</fpage><lpage>4599</lpage><pub-id pub-id-type="doi">10.1074/jbc.R113.488247</pub-id><?supplied-pmid 24362028?><pub-id pub-id-type="pmid">24362028</pub-id></element-citation></ref><ref id="CR193"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>Q</given-names></name><etal/></person-group><article-title>A TALEN genome-editing system for generating human stem cell-based disease models</article-title><source>Cell Stem Cell</source><year>2013</year><volume>12</volume><fpage>238</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2012.11.011</pub-id><?supplied-pmid 23246482?><pub-id pub-id-type="pmid">23246482</pub-id></element-citation></ref><ref id="CR194"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>G</given-names></name><etal/></person-group><article-title>Efficient, footprint-free human iPSC genome editing by consolidation of Cas9/CRISPR and piggyBac technologies</article-title><source>Nat. Protoc.</source><year>2016</year><volume>12</volume><fpage>88</fpage><pub-id pub-id-type="doi">10.1038/nprot.2016.152</pub-id><?supplied-pmid 27929521?><pub-id pub-id-type="pmid">27929521</pub-id></element-citation></ref><ref id="CR195"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>La Manno</surname><given-names>G</given-names></name><etal/></person-group><article-title>Molecular diversity of midbrain development in mouse, human, and stem cells</article-title><source>Cell</source><year>2016</year><volume>167</volume><fpage>566</fpage><lpage>580.e519</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.09.027</pub-id><?supplied-pmid 27716510?><pub-id pub-id-type="pmid">27716510</pub-id></element-citation></ref><ref id="CR196"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arenas</surname><given-names>E</given-names></name><name><surname>Denham</surname><given-names>M</given-names></name><name><surname>Villaescusa</surname><given-names>JC</given-names></name></person-group><article-title>How to make a midbrain dopaminergic neuron</article-title><source>Development</source><year>2015</year><volume>142</volume><fpage>1918</fpage><pub-id pub-id-type="doi">10.1242/dev.097394</pub-id><?supplied-pmid 26015536?><pub-id pub-id-type="pmid">26015536</pub-id></element-citation></ref><ref id="CR197"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kriks</surname><given-names>S</given-names></name><etal/></person-group><article-title>Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson&#x02019;s disease</article-title><source>Nature</source><year>2011</year><volume>480</volume><fpage>547</fpage><pub-id pub-id-type="doi">10.1038/nature10648</pub-id><?supplied-pmid 22056989?><pub-id pub-id-type="pmid">22056989</pub-id></element-citation></ref><ref id="CR198"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chambers</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling</article-title><source>Nat. Biotechnol.</source><year>2009</year><volume>27</volume><fpage>275</fpage><pub-id pub-id-type="doi">10.1038/nbt.1529</pub-id><?supplied-pmid 19252484?><pub-id pub-id-type="pmid">19252484</pub-id></element-citation></ref><ref id="CR199"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perrier</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Derivation of midbrain dopamine neurons from human embryonic stem cells</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2004</year><volume>101</volume><fpage>12543</fpage><pub-id pub-id-type="doi">10.1073/pnas.0404700101</pub-id><?supplied-pmid 15310843?><pub-id pub-id-type="pmid">15310843</pub-id></element-citation></ref><ref id="CR200"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Danes</surname><given-names>A</given-names></name><etal/></person-group><article-title>Efficient generation of A9 midbrain dopaminergic neurons by lentiviral delivery of LMX1A in human embryonic stem cells and induced pluripotent stem cells</article-title><source>Hum. gene Ther.</source><year>2012</year><volume>23</volume><fpage>56</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1089/hum.2011.054</pub-id><?supplied-pmid 21877920?><pub-id pub-id-type="pmid">21877920</pub-id></element-citation></ref><ref id="CR201"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swistowski</surname><given-names>A</given-names></name><etal/></person-group><article-title>Efficient generation of functional dopaminergic neurons from human induced pluripotent stem cells under defined conditions</article-title><source>Stem Cells</source><year>2010</year><volume>28</volume><fpage>1893</fpage><lpage>1904</lpage><pub-id pub-id-type="doi">10.1002/stem.499</pub-id><?supplied-pmid 20715183?><pub-id pub-id-type="pmid">20715183</pub-id></element-citation></ref><ref id="CR202"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebert</surname><given-names>AD</given-names></name><etal/></person-group><article-title>EZ spheres: a stable and expandable culture system for the generation of pre-rosette multipotent stem cells from human ESCs and iPSCs</article-title><source>Stem Cell Res.</source><year>2013</year><volume>10</volume><fpage>417</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1016/j.scr.2013.01.009</pub-id><?supplied-pmid 23474892?><pub-id pub-id-type="pmid">23474892</pub-id></element-citation></ref><ref id="CR203"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>T</given-names></name><etal/></person-group><article-title>Functional neurons generated from T cell-derived induced pluripotent stem cells for neurological disease modeling</article-title><source>Stem Cell Rep.</source><year>2016</year><volume>6</volume><fpage>422</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2016.01.010</pub-id></element-citation></ref><ref id="CR204"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>XQ</given-names></name><name><surname>Zhang</surname><given-names>SC</given-names></name></person-group><article-title>Differentiation of neural precursors and dopaminergic neurons from human embryonic stem cells</article-title><source>Methods Mol. Biol.</source><year>2010</year><volume>584</volume><fpage>355</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1007/978-1-60761-369-5_19</pub-id><?supplied-pmid 19907987?><pub-id pub-id-type="pmid">19907987</pub-id></element-citation></ref><ref id="CR205"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>S</given-names></name><etal/></person-group><article-title>Neurosphere based differentiation of human iPSC improves astrocyte differentiation</article-title><source>Stem Cells Int.</source><year>2016</year><volume>2016</volume><fpage>15</fpage></element-citation></ref><ref id="CR206"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bardy</surname><given-names>C</given-names></name><etal/></person-group><article-title>Predicting the functional states of human iPSC-derived neurons with single-cell RNA-seq and electrophysiology</article-title><source>Mol. Psychiatry</source><year>2016</year><volume>21</volume><fpage>1573</fpage><lpage>1588</lpage><pub-id pub-id-type="doi">10.1038/mp.2016.158</pub-id><?supplied-pmid 27698428?><pub-id pub-id-type="pmid">27698428</pub-id></element-citation></ref><ref id="CR207"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Hurk</surname><given-names>M</given-names></name><name><surname>Bardy</surname><given-names>C</given-names></name></person-group><article-title>Single-cell multimodal transcriptomics to study neuronal diversity in human stem cell-derived brain tissue and organoid models</article-title><source>J. Neurosci. Methods</source><year>2019</year><volume>325</volume><fpage>108350</fpage><pub-id pub-id-type="doi">10.1016/j.jneumeth.2019.108350</pub-id><?supplied-pmid 31310823?><pub-id pub-id-type="pmid">31310823</pub-id></element-citation></ref><ref id="CR208"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bardy</surname><given-names>C</given-names></name><etal/></person-group><article-title>Neuronal medium that supports basic synaptic functions and activity of human neurons in vitro</article-title><source>Proc. Natl Acad. Sci.</source><year>2015</year><volume>112</volume><fpage>E2725</fpage><pub-id pub-id-type="doi">10.1073/pnas.1504393112</pub-id><?supplied-pmid 25870293?><pub-id pub-id-type="pmid">25870293</pub-id></element-citation></ref><ref id="CR209"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cadwell</surname><given-names>CR</given-names></name><etal/></person-group><article-title>Electrophysiological, transcriptomic and morphologic profiling of single neurons using Patch-seq</article-title><source>Nat. Biotechnol.</source><year>2015</year><volume>34</volume><fpage>199</fpage><pub-id pub-id-type="doi">10.1038/nbt.3445</pub-id><?supplied-pmid 26689543?><pub-id pub-id-type="pmid">26689543</pub-id></element-citation></ref><ref id="CR210"><label>210.</label><mixed-citation publication-type="other">van den Hurk, M., Erwin, J. A., Yeo, G. W., Gage, F. H. &#x00026; Bardy, C. Patch-Seq protocol to analyze the electrophysiology, morphology and transcriptome of whole single neurons derived from human pluripotent stem cells. <italic>Front. Mol. Neurosci.</italic><bold>11</bold>, 261 (2018).</mixed-citation></ref><ref id="CR211"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pacelli</surname><given-names>C</given-names></name><etal/></person-group><article-title>Elevated mitochondrial bioenergetics and axonal arborization size are key contributors to the vulnerability of dopamine neurons</article-title><source>Curr. Biol.</source><year>2015</year><volume>25</volume><fpage>2349</fpage><lpage>2360</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2015.07.050</pub-id><?supplied-pmid 26320949?><pub-id pub-id-type="pmid">26320949</pub-id></element-citation></ref><ref id="CR212"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snow</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease</article-title><source>Mov. Disord.</source><year>2010</year><volume>25</volume><fpage>1670</fpage><lpage>1674</lpage><pub-id pub-id-type="doi">10.1002/mds.23148</pub-id><?supplied-pmid 20568096?><pub-id pub-id-type="pmid">20568096</pub-id></element-citation></ref><ref id="CR213"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawakami</surname><given-names>F</given-names></name><etal/></person-group><article-title>LRRK2 phosphorylates tubulin-associated Tau but not the free molecule: LRRK2-mediated regulation of the Tau-tubulin association and neurite outgrowth</article-title><source>PLOS ONE</source><year>2012</year><volume>7</volume><fpage>e30834</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0030834</pub-id><?supplied-pmid 22303461?><pub-id pub-id-type="pmid">22303461</pub-id></element-citation></ref><ref id="CR214"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shachar</surname><given-names>T</given-names></name><etal/></person-group><article-title>Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond</article-title><source>Mov. Disord.</source><year>2011</year><volume>26</volume><fpage>1593</fpage><lpage>1604</lpage><pub-id pub-id-type="doi">10.1002/mds.23774</pub-id><?supplied-pmid 21618611?><pub-id pub-id-type="pmid">21618611</pub-id></element-citation></ref><ref id="CR215"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>AD</given-names></name><name><surname>Mazzulli</surname><given-names>JR</given-names></name></person-group><article-title>Is Parkinson's disease a lysosomal disorder?</article-title><source>Brain</source><year>2018</year><volume>141</volume><fpage>2255</fpage><lpage>2262</lpage><pub-id pub-id-type="doi">10.1093/brain/awy147</pub-id><?supplied-pmid 29860491?><pub-id pub-id-type="pmid">29860491</pub-id></element-citation></ref><ref id="CR216"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dehay</surname><given-names>B</given-names></name><etal/></person-group><article-title>Lysosomal dysfunction in Parkinson disease: ATP13A2 gets into the groove</article-title><source>Autophagy</source><year>2012</year><volume>8</volume><fpage>1389</fpage><lpage>1391</lpage><pub-id pub-id-type="doi">10.4161/auto.21011</pub-id><?supplied-pmid 22885599?><pub-id pub-id-type="pmid">22885599</pub-id></element-citation></ref><ref id="CR217"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sainath</surname><given-names>R</given-names></name><name><surname>Gallo</surname><given-names>G</given-names></name></person-group><article-title>Cytoskeletal and signaling mechanisms of neurite formation</article-title><source>Cell Tissue Res.</source><year>2015</year><volume>359</volume><fpage>267</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1007/s00441-014-1955-0</pub-id><?supplied-pmid 25080065?><pub-id pub-id-type="pmid">25080065</pub-id></element-citation></ref><ref id="CR218"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winans</surname><given-names>AM</given-names></name><name><surname>Collins</surname><given-names>SR</given-names></name><name><surname>Meyer</surname><given-names>T</given-names></name></person-group><article-title>Waves of actin and microtubule polymerization drive microtubule-based transport and neurite growth before single axon formation</article-title><source>eLife</source><year>2016</year><volume>5</volume><fpage>e12387</fpage><pub-id pub-id-type="doi">10.7554/eLife.12387</pub-id><?supplied-pmid 26836307?><pub-id pub-id-type="pmid">26836307</pub-id></element-citation></ref><ref id="CR219"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michel</surname><given-names>PatrickP</given-names></name><name><surname>Hirsch</surname></name><name><surname>Etienne</surname><given-names>C</given-names></name><name><surname>Hunot</surname><given-names>S</given-names></name></person-group><article-title>Understanding dopaminergic cell death pathways in Parkinson disease</article-title><source>Neuron</source><year>2016</year><volume>90</volume><fpage>675</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2016.03.038</pub-id><?supplied-pmid 27196972?><pub-id pub-id-type="pmid">27196972</pub-id></element-citation></ref><ref id="CR220"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doorn</surname><given-names>KJ</given-names></name><etal/></person-group><article-title>Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson's disease patients</article-title><source>Acta neuropathologica Commun.</source><year>2014</year><volume>2</volume><fpage>90</fpage></element-citation></ref><ref id="CR221"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phani</surname><given-names>S</given-names></name><name><surname>Loike</surname><given-names>JD</given-names></name><name><surname>Przedborski</surname><given-names>S</given-names></name></person-group><article-title>Neurodegeneration and inflammation in Parkinson's disease</article-title><source>Parkinsonism Relat. Disord.</source><year>2012</year><volume>18</volume><fpage>S207</fpage><lpage>S209</lpage><pub-id pub-id-type="doi">10.1016/S1353-8020(11)70064-5</pub-id><?supplied-pmid 22166436?><pub-id pub-id-type="pmid">22166436</pub-id></element-citation></ref><ref id="CR222"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGeer</surname><given-names>PL</given-names></name><name><surname>McGeer</surname><given-names>EG</given-names></name></person-group><article-title>Inflammation and neurodegeneration in Parkinson's disease</article-title><source>Parkinsonism Relat. Disord.</source><year>2004</year><volume>10</volume><fpage>S3</fpage><lpage>S7</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2004.01.005</pub-id><?supplied-pmid 15109580?><pub-id pub-id-type="pmid">15109580</pub-id></element-citation></ref><ref id="CR223"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muffat</surname><given-names>J</given-names></name><etal/></person-group><article-title>Efficient derivation of microglia-like cells from human pluripotent stem cells</article-title><source>Nat. Med.</source><year>2016</year><volume>22</volume><fpage>1358</fpage><pub-id pub-id-type="doi">10.1038/nm.4189</pub-id><?supplied-pmid 27668937?><pub-id pub-id-type="pmid">27668937</pub-id></element-citation></ref><ref id="CR224"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwamborn</surname><given-names>JCIsParkinson's</given-names></name></person-group><article-title>Disease a neurodevelopmental disorder and will brain organoids help us to understand it?</article-title><source>Stem Cells Dev.</source><year>2018</year><volume>27</volume><fpage>968</fpage><lpage>975</lpage><pub-id pub-id-type="doi">10.1089/scd.2017.0289</pub-id><?supplied-pmid 29415619?><pub-id pub-id-type="pmid">29415619</pub-id></element-citation></ref><ref id="CR225"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rando</surname><given-names>TA</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name></person-group><article-title>Aging, rejuvenation, and epigenetic reprogramming: resetting the aging clock</article-title><source>Cell</source><year>2012</year><volume>148</volume><fpage>46</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.01.003</pub-id><?supplied-pmid 22265401?><pub-id pub-id-type="pmid">22265401</pub-id></element-citation></ref><ref id="CR226"><label>226.</label><mixed-citation publication-type="other">de Boni, L. &#x00026; W&#x000fc;llner, U. Epigenetic analysis in human neurons: considerations for disease modeling in PD. <italic>Front Neurosci.</italic><bold>13</bold>, 276 (2019).</mixed-citation></ref><ref id="CR227"><label>227.</label><mixed-citation publication-type="other">Magen, I. &#x00026; Chesselet, M.-F. in <italic>Progress in Brain Research</italic>, Vol. 184 (eds Anders Bj&#x000f6;rklund &#x00026; M. Angela Cenci) 53&#x02013;87 (Elsevier, 2010).</mixed-citation></ref><ref id="CR228"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Potashkin</surname><given-names>JA</given-names></name><name><surname>Blume</surname><given-names>SR</given-names></name><name><surname>Runkle</surname><given-names>NK</given-names></name></person-group><article-title>Limitations of animal models of Parkinson's disease</article-title><source>Parkinson#39;s. Dis.</source><year>2011</year><volume>2011</volume><fpage>7</fpage></element-citation></ref><ref id="CR229"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terzioglu</surname><given-names>M</given-names></name><name><surname>Galter</surname><given-names>D</given-names></name></person-group><article-title>Parkinson&#x02019;s disease: genetic versus toxin-induced rodent models</article-title><source>FEBS J.</source><year>2008</year><volume>275</volume><fpage>1384</fpage><lpage>1391</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2008.06302.x</pub-id><?supplied-pmid 18279376?><pub-id pub-id-type="pmid">18279376</pub-id></element-citation></ref><ref id="CR230"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koprich</surname><given-names>JB</given-names></name><name><surname>Kalia</surname><given-names>LV</given-names></name><name><surname>Brotchie</surname><given-names>JM</given-names></name></person-group><article-title>Animal models of alpha-synucleinopathy for Parkinson disease drug development</article-title><source>Nat. Rev. Neurosci.</source><year>2017</year><volume>18</volume><fpage>515</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1038/nrn.2017.75</pub-id><?supplied-pmid 28747776?><pub-id pub-id-type="pmid">28747776</pub-id></element-citation></ref><ref id="CR231"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jagmag</surname><given-names>SA</given-names></name><name><surname>Tripathi</surname><given-names>N</given-names></name><name><surname>Shukla</surname><given-names>SD</given-names></name><name><surname>Maiti</surname><given-names>S</given-names></name><name><surname>Khurana</surname><given-names>S</given-names></name></person-group><article-title>Evaluation of models of Parkinson's disease</article-title><source>Front. Neurosci.</source><year>2016</year><volume>9</volume><fpage>503</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.3389/fnins.2015.00503</pub-id><?supplied-pmid 26834536?><pub-id pub-id-type="pmid">26834536</pub-id></element-citation></ref><ref id="CR232"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cicchetti</surname><given-names>F</given-names></name><etal/></person-group><article-title>Systemic exposure to paraquat and maneb models early Parkinson's disease in young adult rats</article-title><source>Neurobiol. Dis.</source><year>2005</year><volume>20</volume><fpage>360</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1016/j.nbd.2005.03.018</pub-id><?supplied-pmid 16242641?><pub-id pub-id-type="pmid">16242641</pub-id></element-citation></ref><ref id="CR233"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherer</surname><given-names>TB</given-names></name><etal/></person-group><article-title>Mechanism of toxicity in rotenone models of Parkinson's disease</article-title><source>J. Neurosci.</source><year>2003</year><volume>23</volume><fpage>10756</fpage><lpage>10764</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.23-34-10756.2003</pub-id><?supplied-pmid 14645467?><pub-id pub-id-type="pmid">14645467</pub-id></element-citation></ref><ref id="CR234"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dawson</surname><given-names>TM</given-names></name><name><surname>Ko</surname><given-names>HS</given-names></name><name><surname>Dawson</surname><given-names>VL</given-names></name></person-group><article-title>Genetic animal models of Parkinson's disease</article-title><source>Neuron</source><year>2010</year><volume>66</volume><fpage>646</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2010.04.034</pub-id><?supplied-pmid 20547124?><pub-id pub-id-type="pmid">20547124</pub-id></element-citation></ref><ref id="CR235"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>KL</given-names></name><name><surname>Ng</surname><given-names>CH</given-names></name></person-group><article-title>Genetic models of Parkinson disease</article-title><source>Biochim Biophys. Acta</source><year>2009</year><volume>1792</volume><fpage>604</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2008.10.005</pub-id><?supplied-pmid 19000757?><pub-id pub-id-type="pmid">19000757</pub-id></element-citation></ref><ref id="CR236"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramonet</surname><given-names>D</given-names></name><etal/></person-group><article-title>Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2</article-title><source>PLOS ONE</source><year>2011</year><volume>6</volume><fpage>e18568</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0018568</pub-id><?supplied-pmid 3071839?><pub-id pub-id-type="pmid">21494637</pub-id></element-citation></ref><ref id="CR237"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease</article-title><source>Nat. Neurosci.</source><year>2009</year><volume>12</volume><fpage>826</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1038/nn.2349</pub-id><?supplied-pmid 19503083?><pub-id pub-id-type="pmid">19503083</pub-id></element-citation></ref><ref id="CR238"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gubellini</surname><given-names>P</given-names></name><name><surname>Picconi</surname><given-names>B</given-names></name><name><surname>Di Filippo</surname><given-names>M</given-names></name><name><surname>Calabresi</surname><given-names>P</given-names></name></person-group><article-title>Downstream mechanisms triggered by mitochondrial dysfunction in the basal ganglia: from experimental models to neurodegenerative diseases</article-title><source>Biochim. Biophys. Acta</source><year>2010</year><volume>1802</volume><fpage>151</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2009.08.001</pub-id><?supplied-pmid 19683569?><pub-id pub-id-type="pmid">19683569</pub-id></element-citation></ref><ref id="CR239"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robert</surname><given-names>C</given-names></name></person-group><article-title>Microarray analysis of gene expression during early development: a cautionary overview</article-title><source>Reproduction</source><year>2010</year><volume>140</volume><fpage>787</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1530/REP-10-0191</pub-id><?supplied-pmid 20833752?><pub-id pub-id-type="pmid">20833752</pub-id></element-citation></ref><ref id="CR240"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brennand</surname><given-names>KJ</given-names></name><etal/></person-group><article-title>Creating patient-specific neural cells for the in vitro study of brain disorders</article-title><source>Stem Cell Rep.</source><year>2015</year><volume>5</volume><fpage>933</fpage><lpage>945</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2015.10.011</pub-id></element-citation></ref><ref id="CR241"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toulorge</surname><given-names>D</given-names></name><name><surname>Schapira</surname><given-names>AH</given-names></name><name><surname>Hajj</surname><given-names>R</given-names></name></person-group><article-title>Molecular changes in the postmortem parkinsonian brain</article-title><source>J. neurochemistry</source><year>2016</year><volume>139</volume><issue>Suppl 1</issue><fpage>27</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1111/jnc.13696</pub-id></element-citation></ref><ref id="CR242"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartmann</surname><given-names>A</given-names></name></person-group><article-title>Postmortem studies in Parkinson's disease</article-title><source>Dialogues Clin. Neurosci.</source><year>2004</year><volume>6</volume><fpage>281</fpage><lpage>293</lpage><?supplied-pmid 3181805?><pub-id pub-id-type="pmid">22033507</pub-id></element-citation></ref><ref id="CR243"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chailangkarn</surname><given-names>T</given-names></name><etal/></person-group><article-title>A human neurodevelopmental model for Williams syndrome</article-title><source>Nature</source><year>2016</year><volume>536</volume><fpage>338</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1038/nature19067</pub-id><?supplied-pmid 27509850?><pub-id pub-id-type="pmid">27509850</pub-id></element-citation></ref><ref id="CR244"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emborg</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Induced pluripotent stem cell-derived neural cells survive and mature in the nonhuman primate brain</article-title><source>Cell Rep.</source><year>2013</year><volume>3</volume><fpage>646</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2013.02.016</pub-id><?supplied-pmid 23499447?><pub-id pub-id-type="pmid">23499447</pub-id></element-citation></ref><ref id="CR245"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kikuchi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Survival of human induced pluripotent stem cell-derived midbrain dopaminergic neurons in the brain of a primate model of Parkinson's disease</article-title><source>J. Parkinsons Dis.</source><year>2011</year><volume>1</volume><fpage>395</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.3233/JPD-2011-11070</pub-id><?supplied-pmid 23933658?><pub-id pub-id-type="pmid">23933658</pub-id></element-citation></ref><ref id="CR246"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kikuchi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Human iPS cell-derived dopaminergic neurons function in a primate Parkinson's disease model</article-title><source>Nature</source><year>2017</year><volume>548</volume><fpage>592</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1038/nature23664</pub-id><?supplied-pmid 28858313?><pub-id pub-id-type="pmid">28858313</pub-id></element-citation></ref><ref id="CR247"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinbeck</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Optogenetics enables functional analysis of human embryonic stem cell-derived grafts in a Parkinson's disease model</article-title><source>Nat. Biotechnol.</source><year>2015</year><volume>33</volume><fpage>204</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1038/nbt.3124</pub-id><?supplied-pmid 25580598?><pub-id pub-id-type="pmid">25580598</pub-id></element-citation></ref></ref-list></back></article>